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EXECIJTTVE SUMMARY
In 1991 the lllawarra Pharmacists Association in conjunction with the lllawarra
Public Health Unit and the University of Wollongong Department of Mathematics
undertook the Pharmacy Exit Survey. This was a cross-sectional survey
administered to purchasers of anti-asthma medications throughout community
pharmacies in the lllawarra. This survey was repeated in 1995 allowing evaluation
of improvements in adult asthma between 1991 and 1995 possibly due to local and
national initiatives.
Indicators of asthma management are described in terms of the National Asthma
Campaign recommendations. These parameters are compared between those
obtaining their p-agonists primarily over the counter and those who obtain them
primarily by prescription, as well as analysing changes between the 1991 and 1995
samples. Potential confounders such as age, sex and severity indicators were
controlled for using the stepwise logistic regression procedure. Crude prevalence
estimates of asthma management factors were weighted using data from a second
study utilising routinely collected drug prescription information, in an attempt to
adjust for the potential bias from an oversampling of those who purchased their
medications more frequently.
Of the respondents 35.4 percent reported primarily obtaining |3-agonist inhalers
over the counter. The prescription group had more severe asthma than the 'over
the counter' group. The 'over the counter' group was less likely to wheeze at least
once per week (P=0.005, OR=0.59, CI=0.39-0.96), to have had at least five attacks
of asthma or wheeze in the last year (P=0.001, OR=0.54, CI=0.35-0.80), to have
been admitted to hospital within the last 12 months (P=0.002, OR=0.31, Cl=0.160.62), and to use a p-agonist inhaler at least daily (P=0.004, OR=0.64, Cl=0.420.99).

Even after taking into account differences in disease severity, the 'over the counter'
group was less likely to have objective airways measurement by the doctor usually
or always (P=0.007, OR=0.37, CI=0.21-0.67), to have a written action plan
(P=0.008, OR=0.48, CI=0.26-0.88) and to have regular medical review at least once
per year (P=0.001, OR=0.50, CI=0.27-0.93). The 'over the counter group' was also
less likely to use preventative medication (P=0.001, OR=0.29, Cl=0.16-0.51) or
ipratropium bromide (P=0.001, OR=0.27, CI=0.09-0.88) regularly during the
previous six months, and less likely to use inhaled corticosteroids (P=0.004,
OR=0.35, Cl=0.21-0.61), and ipratropium bromide (P=0.001, OR=0.44, Cl=0.200.94) at any time.

Between 1991 and 1995 there was no significant improvement in non-drug related
asthma management indicators. Prescribing patterns improved with increases in the
regular use of inhaled corticosteroids or sodium cromoglycate (P=0.001, OR=0.87,
CI=0.80-0.95) and an increase in the use at any time of sodium cromoglycate
(P=0.033, OR=0.87, Cl=0.80-0.95). The use of medications which may be
inappropriate for asthma (eg. antibiotics), are still prevalent however there has been
a reduction in the use of theophylline both regularly (P=0.001, 0R=1.27, Cl=1.141.41) and at any time (P=0.001, 0R=1.27, Cl=1.15-1.40). These improvements in
prescribing are in line with the recommendations of the Asthma Management Plan.
Improvements in asthma management however are sub-optimal, particularly in
relation to the 'over the counter' group. Targetted local initiatives are needed to
improve adult asthma management in the lllawarra region, supporting programs
from the National Asthma Campaign and any state-wide initiatives.

1. INTRODUCTION

There has been a number of local programs in the lllawarra which were aimed at
improving asthma management. The first of these involved 94 per cent of community
pharmacies in a regional research program which aimed to identify barriers to asthma
management and problems implementing the "Pharmacists Asthma Management Plan".
Several interested pharmacists then participated in focus groups to further examine the
issue, and were finally brought together with a group of lllawarra general practitioners
to examine common problems.^

The National Asthma Campaign began in 1990, with the first phase concentrating on
health professionals: doctors, pharmacists, nurses and ambulance officers.^

The

National Asthma Campaign produced and mailed 28 000 detailed educational booklets
to general practitioners across Australia, together with information pamphlets for
patients and cards to aid doctors in producing individualised action plans for their
patients.

The National Asthma Campaign also took out more than 30 two page

advertisements in the most frequently read medical journals promoting the Asthma
Management Plan, the use of peak flow meters and preventative medications.^

The second phase of the campaign was directed at the asthma sufferer and aimed to
increase knowledge about asthma and health lifestyle. This phase consisted of an
education program run through schools, unions and employer groups and distribution
of the Asthma Management Plan through health care providers.'^

The third phase in mid 1991 was a major asthma awareness media campaign directed
at the general public. It aimed to inform the general community of the limitations of
using inhaled bronchodilator medication to treat asthma. This phase of the campaign
was based around a 30 second television public service announcement. This depicted
a colourless male robotic figure who repetitively overuses bronchodilator medication
untill he hears a new message about asthma management. He aquires an asthma
action plan and becomes more human. The final message states that people should

turn to their health professional to learn prevention, leading to a symptom free life.®

Few studies have examined asthma management in the Australian community. These
surveys give some indication of the effect of both local and national initiatives in asthma
management. They provide the basis for objective measurement of application by
health professionals and acceptance by consumers of National Asthma Campaign
guidelines. The baseline measurement in 1991 showed areas of sub-optimal asthma
management and the analysis of both the 1991 and 1995 data will give an assessment
of changes in practice over this time frame.

2. BACKGROUND
Asthma is defined as a chronic inflammatory condition of the airways characterised by
bronchial mucosal inflammation, with oedema, infiltration with inflammatory cells
(especially eosinophils), hypertrophy of glands and smooth muscle and damaged
epithelium. Symptoms include wheezing, coughing, chest tightness and shortness of
breath. This condition may lead to irreversible obstruction of air flow in some chronic
patients.®'"^®
Asthma is a significant problem in Australia both in terms of mortality and morbidity as
well as cost to the Australian community.®'^® In 1991 the total cost burden of asthma in
Australia was estimated to be between $585 and $720 million. This comprised of $320
million of direct medical costs and between $260 and $400 million indirect costs.
Indirect costs are those due to lost productivity to society due to asthma. It includes the
costs of invalidity, absenteeism, reduced effectiveness whilst at work, and work time
lost from attending appointments. The direct medical costs are made up of general
practitioner time, medication, specialist time, emergency attendances, hospital
outpatient and inpatient services.^^ Asthma is also one of the most common causes of
admission to hospital. Asthma is a high priority on the health agenda because it is a
largely manageable disease. Well managed sufferers can usually lead perfectly normal
lives.
The 1989-90 National Health Survey run by the Australian Bureau of Statistics
estimated that 1.4 million or between 8-9 per cent of all Australian are clinically
diagnosed asthmatics.^^ This finding was supported by a National Asthma Campaign
baseline survey which estimated prevalence in adults aged 12 and over to be 7 per
cent.^^ Bauman ef a/in a survey of a stratified random sample of schoolchildren and
their parents from schools in Sydney, Melbourne, Brisbane and the Upper Hunter
Valley (New South Wales) found 19 percent of adults reporting wheeze symptoms in
the previous 12 months and 7.2 per cent had diagnosed asthma.""^ A repeat of this
survey in 1993, found no significant change in reported wheezing or in diagnosis of

asthma in adults.^®

The National Asthma Campaign was initiated in 1989 with the aim of improving asthma
management through promotion of a recognised Asthma Management Plan which was
devised by the Thoracic Society of Australia and New Zealand.^® The latest revision
of the Asthma Management Plan was published in 1993 by the National Asthma
CampaignJ^

This approach is widely recommended however it has not been

unequivocally shown to lead to improved asthma control.^®

The Asthma Management Plan is made up of six clear steps which can be followed by
clinicians. It draws on evidence that many asthma deaths are associated with under
treatment related to an over-reliance on bronchodilators and under use of inhaled and
oral corticosteroids, failure to make objective measurement of disease severity and
inadequate supervision.''®'^^'^^'^'^^ Regular use of inhaled corticosteroids is emphasised
in the Asthma Management Plan, even for those patients of moderate disease severity.
Inhaled corticosteroids are extremely important as they act directly on the airways to
reduce inflammation and bronchial hyper responsiveness, p-agonists on the other
hand can only alleviate the symptoms of asthma and do nothing to alter the underlying
disease process.^"^

Sears et al found in a double blinded, placebo-controlled,

randomised crossover study that regular inhalation of p-agonist drugs was associated
with a deterioration of asthma control in the majority of subjects compared with pagonist use for symptom relief only.^^

Written action plans are also a very important component of the Asthma Management
Plan as an inability to recognise deteriorating asthma has been suggested as an
important preventable factor in asthma d e a t h s . A s t h m a self management plans
are essential in the long term management of adult asthmatics because they help
people to recognise deteriorating asthma and initiate early and appropriate treatment.^^
Charlton et al have challenged the need for a peak flow meter in order to implement
self management plans. They tested through a randomised follow-up trial two self
management plans, the first measuring peak expiratory flow and the second based

purely on symptoms. Both self management plans produced significant reductions in
the measured outcomes, however there were no significant differences between the
groups using the different plans. It was concluded that the peak flow meter was not the
crucial ingredient in the decreasing morbidity of the two groups of asthmatics and that
teaching patients the importance of their symptoms and the appropriate action to take
when their asthma deteriorates is the key to effective management of asthma.^®

Step 1 of the Asthma Management Plan involves assessing the overall severity of the
disease. Step 2 deals with achieving the best possible lung function. Step 3 involves
maintaining that best possible lung function through home monitoring of peak expiratory
flow, drug therapy and avoidance of trigger and aggravating factors.

Step 4 is

concerned with developing an action plan including recognising indicators of worsening
asthma, developing the written crisis plan and knowing how best to seek medical help.
This action plan should be reviewed after attacks.

Step 5 deals with educating,

supporting and counselling the patient and family, and step 6 encourages regular
review of the patient.

Because of the very high prevalence of asthma, the condition is often managed in the
primary health care setting by general p r a c t i t i o n e r s ^ ^ a n d by pharmacists. Tse et
al in 1991 found that most general practitioners around Australia knew and reported
practicing appropriate asthma management, however room for improvement was found
in regards to the understanding and use of theophyllines, the use of preventative
medications such as inhaled steroids and sodium cromoglycate, the use of crisis
planning for severe attacks and lung function measurement.^"^ Fardy and Jeffs in the
lllawarra found asthma knowledge of general practitioners to be very high, with 88 per
cent of general practitioners scoring more than 86 per cent on a test.^^ The results of
a "subsample" of lllawarra general practitioners from a national general practitioner
survey^® showed reported management practices were generally of a high standard,
however they were not entirely consistent with the Asthma Management Plan, lllawarra
general practitioners were no different to those of the national sample. The results
suggested that lllawarra general practitioners were

inappropriately prescribing

theophyllines and that inhaled steroids and sodium cromoglycate were being
underused as preventative medications.

Only 40 per cent of lllawarra general

practitioners were developing written crisis plans for patients and only 36 per cent
reported measuring airways function at most visits.^^ Beilby ei a/found no significant
differences in methods of treatment of adults with asthma between city and country
general practitioners.^®

The National Asthma Campaign was effective in making general practitioners aware
of the principles of good asthma management. As mentioned earlier, the first stage of
the campaign basically consisted of a mail out package to general practitioners of
information and aids to good management as well as a series of advertisements in
medical journals promoting the principles of the Asthma Management Plan. After the
campaign general practitioners reported significant improvements in ainA/ay function
measurement practices, the use of preventative drug therapy and the use of written
action plans.^® A population based approach has also been taken in evaluating the
National Asthma Campaign. After the campaign there was an increase in the use of
inhaled corticosteroids and a decrease in the use of theophyllines. Measurement of
lung function by a doctor in the previous year, ownership of a peak flow meter, and
possession of a written action plan all increased."^ All of these changes are in line with
the Athma Management Plan."^^

It has also been suggested that the Asthma Management Plan may not be appropriate
or feasible for general practitioners as it was written by specialist respiratory
physicians, and there are differences between the spectrum of patients and severity of
diseases encountered by specialists and general practitioners'^^'^^. Kelly et al in a study
of community pharmacists in the lllawarra found that pharmacists also had problems
implementing the "Pharmacists Asthma Management Plan". Aspects of the plan which
pharmacists had most difficulty implementing were ensuring people with asthma had
a written action plan, identifying undiagnosed asthmatics, ensuring people with asthma
know why and how a peak flow meter is used, and advising on identification and
avoidance of trigger factors. Barriers were identified to improved asthma management.

These included a lack of time, a lack of renumeration for counselling, and a customer
attitude of reluctance to discuss their condition and a primary lack of awareness of the
need for preventative medication. Aspects of the plan pharmacists had least difficulty
implementing included ensuring an understanding of the difference between 'reliever'
and 'preventer* medication, ensuring correct inhaler technique, identifying and referring
frequent users of p-agonists, and emphasising and assisting with compliance/"^

In 1975 salbutamol, terbutaline and feneterol were moved from schedule 4 (prescription
only) to schedule 3 (available from a pharmacists without a prescription) in NSW with
other states doing the same through to 1983. The benefits of such a move included a
financial gain for the community because of a reduction in asthmatics consulting a
doctor just for a script as well as making these reliever medications easily accessible
to the community. Potential risks included: and increase in unsupervised use of (3agonist aerosols; reduced access to education about asthma; delays in seeking
essential treatment for worsening asthma, and a development of excessive
dependence on them limiting the use of other drugs which can only be obtained with
a prescription."^® Jenkins et al in a study of data of prescribed antiasthmatic drugs
reported that non-prescription sales of salbutamol inhalers increased 410 per cent from
1980-6.^®

An important issue in the current management of asthma is the potential problems
associated with overuse of p-agonists. Sears ef a/compared the control of asthma
during two regimes of fenetorol use.

In most cases, control of asthma was less

effective with regular use of high doses of feneterol than with use as dictated by
necessity."^^

Haahtela et al found that antiinflammatory therapy with inhaled

budesonide (inhaled corticosteroid) to be an effective first-line treatment for patients
with newly detected, mild asthma. It was found to be superior to the use of terbutaline
(P-agonist) in such patients."^®

Henry ef a/compared asthmatics aged 13-55 years in the Hunter Valley region of New
South Wales who either used purchase as their sole means of acquiring metered dose

inhalers and used no prescription medication, or who used a prescription to obtain
some or all of their asthma drugs. Of all salbutamol inhalers dispensed, 40 per cent
were purchased over the counter. They found 97.5 per cent of the purchase group
were undertreated, in that they required either inhaled or oral steroids and 47 per cent
of the prescription group received inadequate treatment. They also found that the
purchase group "seldom" visits the doctor (general practitioners or specialists). They
concluded that the present scheduling of P-agonists continues to legitimise the
unsupervised use of bronchodilater aerosols as a sole treatment by significant numbers
of asthmatics in Australia.'^^
Marias ef a/in a study of asthmatics in Lismore, New South Wales in 1994, found that
many participants with moderate or severe asthma were not managed in accordance
with the recommendations of the asthma management plan.

In particular small

proportions took inhaled steroids, used a peak flow meter or had a written action plan.
Excess use of p-agonists were not however found to be a significant problem^®
Westley-Wise e i a/(1991) found in a review of pharmacy databases in the lllawarra,
that of those prescribed an average of more than 6 inhalations of p-agonists daily, 19
per cent were not prescribed any preventative medications and 36 per cent were
prescribed an average of less than 2 inhalations of preventative medication daily.^^
This represented relatively poor drug therapy in the overall management of asthmatics
in the area. They estimated that at least 40 per cent of asthmatics were receiving
inadequate doses of inhaled preventative medications.

A study of 434 adult P-agonist purchasers in the lllawarra in 1991 found that 39 per
cent purchased their p-agonist medications primarily over the counter.^^ The over the
counter group was younger, and less likely to report regular peak flow measurement
by the doctor. The group mostly obtaining their p-agonists medicators by prescription
was more likely to have regular routine medical review, and more likely to use inhaled
preventative medication regularly. They also found significant use of medications
which may be contraindicated for people with asthma, including the use of

theophyllines without the use of inhaled corticosteroids which the Asthma Management
Plan®^ specifically advises against.

3. RESEARCH QUESTIONS

The aim of the Pharmacy Exit Survey is to identify current asthma management
practices in terms of utilisation of:

preventative medication and p-agonists,
medications which may be contraindicated for people with asthma,
peak flow meters for self-monitoring and monitoring by doctors,
written management plans, and
routine medical review.

It is also aimed to compare indicators of disease severity and appropriateness of
asthma management practices between those who predominantly obtained their pagonist inhalers over the counter (the OTC group) and those who obtained them mainly
by prescription (the prescription group).

The aim of the Drug Utilisation Survey is to provide information related to the
prescribed medication obtained by users of anti-asthma medications in the lllawarra
including:

•

preventative medications and p-agonists, and

•

medications which may be contraindicated for people with asthma.

For the purpose of this study, the Drug Utilisation Survey aims to provide information
of the frequency of visits to community pharmacies to have prescriptions filled for pagonists and the frequency of visits for all anti-asthma medications. These measures
are used to weight prevalence estimates of asthma management factors to adjust for
the potential over sampling of those who more regularly obtain anti-asthma medications
from community pharmacies.

These surveys were first carried out in 1991 by the lllawarra Pharmacists Association
in conjunction with the lllawarra Area Health Service Public Health Unit and the
University of Wollongong Department of Mathematics. The results of these surveys are
reported elsewhere.®"^-®®
These surveys were repeated in 1995. The aim is to analyse changes in asthma
management practices between 1991 and 1995 which may be due to local or national
initiatives which occurred during this period.

11
3 0009 03201128 5

4.

MCTHODS

A literature search was carried out using M E D L I N E database from years 1990 to 1996
a n d C I N A H L (Nursing a n d Allied Health) databases from years 1982 to 1996. Key
search terms included asthma, management, adult and Australia. References from the
results of t h e original search were used to extend searches.

Literature was also

obtained f r o m a r e a health service reports and local publications.

The same methodology w a s used in 1995 as in 1991, except for slight c h a n g e s to the
q u e s t i o n n a i r e , a n d minor differences in the methods of analysis from the original
study.®® R e p o r t e d here are the results of identical analysis of both 1991 a n d 1995
Pharmacy Exit Survey data, except in relation to question 13 which was added in 1995.
All p h a r m a c i e s (66) in the lllawarra area were asked to participate. Each pharmacist
was a s k e d to recnjit 12 consecutive clients aged 15 years or over obtaining any antiasthmatic medications (P-agonists, theophyllines, inhaled corticosteroids, ipratropium,
or s o d i u m cromoglycate) to fill in the one page questionnaire. Each pharmacist
completed a data sheet including: the gender and age (estimated for non-responders);
their a n s w e r s to two questions derived from a previously validated questionnaire®^
( c o n c e r n e d with previous asthma diagnosis and chronic sputum production); and
w h e t h e r they a g r e e d or refused to complete the questionnaire.

The questions

concerned with sputum production and asthma diagnosis were used to exclude people
with chronic bronchitis (defined as reporting chronic sputum production a n d never been
d i a g n o s e d with a s t h m a ) at the d a t a analysis stage.

T h e 1991 a n d 1995 participant information sheets and questionnaires are shown in
a p p e n d i c e s 2 a n d 3 respectively. The questionnaires include questions related to
a s t h m a m a n a g e m e n t practices such as use of peak flow meters, written plans,
medication, a n d medical supervision. Also included are questions related to a s t h m a
severity such as frequency of wheezing and "attacks" of a s t h m a and wheeze, previous
hospitalisation, a n d frequency of use of p-agonist inhalers. In addition there w a s one
question about the frequency of visits to community pharmacies to obtain anti-asthma

medications. The questionnaire was altered slightly from 1991 to 1995. Changes were
made in Question 1 and Question 11 due to changes in the availability of brand name
dnjgs, as well as other minor changes in question expression. Slight wording changes
can also be noted in Question 3 and Question 7. These wording changes were
unintentional, however they are not expected to influence the responses in any manner.
Question 13, which related specifically to the frequency of visiting community
pharmacies to have scripts filled for p-agonists, was also added to the questionnaire
in 1995. Question 12, which is primarily used for weighting the asthma management
prevalence estimates, obtains the frequency of pharmacy visits to obtain medication
"for your chest". The corresponding Information from the Drug Utilisation Survey
measures the frequency of visits to community pharmacies to have prescriptions filled
for either all anti-asthma medications or for p-agonist medications.

Question 13

therefore is a more specific question which collects information which is more
appropriate for the weighting methodology used.
The data were entered into Epilnfo v5.1. The data were analysed using SAS v6.10 for
Windows. Prevalence estimates were made of indicators related to asthma severity
and asthma management.

Crude odds ratios are used to compare severity and

asthma management indicators between groups who reported mainly obtaining Pagonists over the counter or mainly by prescription in 1995 and between the 1991 and
1995 groups. Statistical significance was established by means of the Chi-squared
test. Confidence limits of the crude odds ratios were calculated by the methods of
Cornfield using Epilnfo v6.0.^®
The cnjde odds ratios for potential measures of disease severity were adjusted for age
and sex by logistic regression analysis. The crude odds ratios for asthma management
indicators were adjusted for potential confounders such as age, sex and severity using
stepwise logistic regression analysis. Indicators of disease severity controlled for in the
analysis were frequency of wheezing (categorised as at least weekly, at least most
days, and at least daily), frequency of asthma attacks (categorised as at least five and
at least 10 in the last year), frequency of pharmacy visits to obtain "chest" medication

(categorised as at least once in the last 12 months, at least 3-4 times, at least 5-10
times, at least 11-25 times and more than 25 times), previous hospitalisation
(characterised as ever and within the last year), and frequency of inhaler use
(characterised as at least once a week, a few times per week, once a day, five times
a day, and more than ten times a day). The logistic regression analyses were also run
without including frequency of inhaler use as an indicator of disease severity.
Statistical significance are shown at the 0.05 level with 95 per cent confidence limits.
In order to adjust prevalence estimates for the potential bias from an oversampling of
those who purchase their asthma medications more frequently, crude weighting factors
were devised based on the reported frequency of pharmacy visits. Estimates were
made of the proportions of the population visiting pharmacies on various numbers of
occasions in the previous year based upon the patient profile developed in a Drug
Utilisation Survey. A sample of lllawarra pharmacists was asked to produce a patient
profile for the previous 12 months of a systematic sample of 15 clients who obtained
(B-agonist medication by prescription on at least one occasion. Data were obtained for
284 patients and included the names, doses, quantities and dates of all medications
obtained on prescription. Only partial information on age was obtained. Two different
weighting factors were devised. The first was based on self reported frequency of
pharmacy visits to obtain anti-asthma medication and the second on frequency of
pharmacy visits to have prescriptions filled for p-agonist drugs. The weighting factors
were calculated by dividing the population distribution by the sample distributions.
These weighting systems were used for both the group mainly obtaining their P-agonist
inhalers over the counter and those mainly using a prescription. Due to only 35 per cent
of Drug Utilisation Survey patient profiles containing information on age, some are
likely to be for those aged less than 15 years. The Pharmacy Exit Survey was only for
those aged 15 years and over.

The following classifications were used for anti-asthma drugs in this study. This
classification is presented in full in the Pharmacists Asthma Management Handbook.^®
The first group of dnjgs are reliever medications (brand names for the drugs are shown

in italics). The primary reliever drugs used are p-agonists which come in both shortacting [eg. salbutamol {Asmol, Respolin, Ventolin); terbutaiine {Bhcanyl)\ fenoterol
hydrobromide (Berotec)] and long-acting [eg. salmeterol {Serevent)] forms. The second
group of reliever drugs are theophyllines [eg. Austyn, Elixophyllin, Nuelin, Slo-Bid,
Theo-Dui] which are now considered to have limited importance in the treatment of
asthma. The final reliever drug is ipratropium bromide [Atrovenf\ which is an anticholinergic bronchodilator.

The second classification of drugs are preventive medications. Sodium cromoglycate
llntal\ is the first of this drug classification. Sodium cromoglycate inhibits the release
of mediators of the allergic reaction from sensitised cells, preventing both the
immediate and late asthmatic responses to stimuli. The second preventive medicator
is Nedocromil sodium ITilade] which is mainly used in adults and children over 12 years
of age. The third group of drugs in this classification are Inhaled Corticosteroids [eg.
beclomethasone [Aldecin, Becioforte, Becotide]\ budesonide [Pulmicoi1\\ fluticasone
[flixotide].

This group of drugs is the main preventive therapy for adults. Nebulised

Corticosteroids are also available eg. budesonide [Pulmicoi1\ however their use is
limited.

The final group of preventive medications are oral corticosteroids eg.

prednisolone and prednisone which are considered the most effective emergency
medication for an acute asthma attack not responding to p-agonist.

5. RESULTS
5.1 1995 Pharmacy Exit Survey
Six hundred and eighty three purchasers of anti-asthma medications aged 15 years and
over were asked to fill in the one page written questionnaire. Of these 507 agreed
giving a response rate of 74.2 per cent. Eighteen respondents reported chronic sputum
production (at least 3 months continually) without being diagnosed with asthma and
were excluded from further analysis. A comparison between respondents and nonrespondents of the written questionnaire is presented in Table 1.
The median age of the respondents was 40 years with 47.9 per cent being male
compared with 36 years and 53.8 per cent respectively for non-respondents. Ninety
per cent of respondents reported having been diagnosed with asthma by a doctor
compared with 86 per cent of non-respondents. Forty three per cent of respondents
and 40.5 per cent of non-respondents reported chronic sputum production.

The

proportion of non-respondents obtaining their p-agonist inhalers over the counter on
this occasion was 55.6 per cent compared with 40.2 per cent of respondents. Of the
respondents 20.5 per cent reported that they always, and a further 14.9 per cent
reported that they usually obtained their p-agonist medications over the counter, while
51.1 per cent indicated that they always and 13.5 per cent usually used a prescription
to obtain their 3-agonist medication.
The respondents were more likely to have had their asthma diagnosed by a doctor (OR
= 2.09, P = 0.022) and less likely to have obtained their anti-asthma medication over
the counter on this occasion (OR = 0.54, P = 0.00082). There was no significant
difference (using t-test) between the respondents and non-respondents in age (P =
0.055), the proportion of males (OR = 0.79, P = 0.186), nor the proportion who reported
chronic cough and sputum (OR = 0.93, P = 0.741).

Table 1: Comparison of questionnaire respondents and non-respondents

Respondents

Nonrespondents

age (years)*

43.6 (40)
n = 491

42.6 (36)
n = 174

sex (M)

47.9%
n = 472

53.8%
n = 173

0.79
(0.55-1.14)

0.186

asthma
diagnosis by
doctor

93.6%
n = 390

87.5%
n = 144

2.09
(1.05-4.13)

0.022

chronic cough
and sputum

43.0%
n = 335

40.5%
n = 123

0.93
(0.60-1.44)

0.741

obtained
medication
'over-thecounter'

40.2%
n = 378

55.6%
n = 171

0.54
(0.37-0.79)

0.00082

test.

Odds Ratio
(95% CI)
-

P value
0.055

in parentheses. Difference tested using a t-

Respondents were classified as either mainly obtaining their anti-asthmatic medications
over the counter or by prescription based upon their self reported frequency of using
a doctors prescription to obtain p-agonist inhalers. Of the respondents 35.4 per cent
reported never (20.5 per cent) or mostly not (14.9 per cent) using a prescription to
obtain inhalers. These respondents were classified as mainly obtaining inhalers over
the counter. Of the respondents 64.6 per cent reported mostly (13.5 per cent) or
always (51.1 per cent) using a prescription to obtain inhalers and were hence
categorised as mainly obtaining their inhalers by prescription.

A comparison of those respondents predominantly obtaining their p-agonist inhalers
over the counter and those using a prescription is shown in Table 2. The median age
of the OTC group was 31 years compared with 50 years for the prescription group. The
age difference was highly significant (P = 0.001). The OTC group (56.6 per cent) was

more predominantly male (OR = 1.74, P = 0.004) than the prescription group (42.8 per
cent). Of the prescription group, 48.1 per cent reported chronic cough and sputum
compared with 32.5 per cent of the OTC group. There was no difference found in the
proportion having asthma diagnosed by the doctor (OR = 0.98, P = 0.956).

Table 2: Comparison of 'OTC group' and 'Prescription group'

OTC group

Prescription
group

age (years)*

34.0 (31)
n = 171

48.5 (50)
n = 312

sex (M)

56.6%
n = 168

42.8%
n = 297

1.74
(1.17-2.60)

0.004

asthma diagnosis
by doctor

93.7%
n = 142

93.8%
n = 242

0.98
(0.39-2.49)

0.956

Odds ratio
(95% CI)
-

P value
0.001

0.52
chronic cough and 32.5%
48.1%
0.006
sputum
n = 120
n = 210
(0.32-0.85)
* Mean ages reported with median ages in parentheses. Difference tested using a ttest.
Table 3 shows indicators of disease severity compared between the OTC group and
the prescription group.
Of the respondents 69.6 percent reported at least daily use of their p-agonist inhalers
and 18.1 per cent at least five times daily use, 60.6 per cent reported wheezing at least
most days and 28.5 per cent every day, 51.0 per cent reported at least five attacks
within the previous twelve months and 36.5 per cent reported at least ten attacks. Of
the respondents 55.0 percent had been admitted to hospital with 'asthma' or 'wheeze'
at least once previously and 13.7 per cent were admitted within the previous year.

Table 3: Potential measures of disease severity compared between the 'OTC
group' and the 'Prescription group'

OTC
group

Prescription
group

Crude odds
ratio
(95% CI)

Adjusted
odds ratio
(95% CI)

P
value

wheeze at least
once per week

69.5%
n = 167

80.9%
n = 303

0.54
(0.34-0.85)

0.59
(0.39-0.96)

0.0320

wheeze most or
every day

49.1%
n = 167

67.0%
n = 303

0.48
(0.32-0.71)

0.55
(0.36-0.84)

0.0052

wheeze every day

20.4%
n = 167

33.0%
n = 303

0.52
(0.32-0.83)

0.66
(0.40-1.07)

0.0945

at least 5 attacks
in the last year

39.2%
n = 171

57.6%
n = 309

0.47
(0.32-0.71)

0.54
(0.35-0.80)

0.0039

at least 10 attacks
last year

25.7%
n = 171

42.4%
n = 309

0.47
(0.31-0.72)

0.51
(0.33-0.80)

0.0035

hospital admission
ever for asthma or
wheeze

54.8%
n = 168

55.1%
n = 305

0.99
(0.66-1.47)

0.79
(0.52-1.20)

0.2746

hospital admission
within the last 12
months

7.14%
n = 168

17.4%
n = 305

0.37
(0.18-0.73)

0.31
(0.16-0.62)

0.0009

use of betaagonist puffer at
least daily

61.4%
n = 175

74.1%
n = 309

0.56
(0.37-0.85)

0.64
(0.42-0.99)

0.0451

use of betaagonist puffer at
least 5 times daily

15.2%
n = 168

19.7%
n = 305

0.73
(0.43-1.24)

0.79
(0.46-1.38)

0.4122

more than 25
visits to pharmacy
for medication

8.24%
n = 170

20.9%
n = 307

0.34
(0.18-0.65)

0.42
(0.21-0.82)

0.0112

These potential measures of disease severity were compared between the two groups.
In the crude analysis and after adjusting for age and sex the OTC group was less likely
to report wheezing at least once per week (OR = 0.59; 95% CI = 0.39-0.96; P = 0.0320)
as well as at least most days (OR = 0.55; 95% CI = 0.36-0.84; P = 0.0052). In the

crude analysis, the OTC group was less likely to report wheezing every day (OR = 0.52,
P = 0.004) however after adjusting for differences in age and sex, this difference was
not significant (OR = 0.66, 95% CI = 0.40-1.07; P = 0.0945).

The prescription group was more likely to have had at least 5 attacks in the last year
(OR = 0.54, 95% CI = 0.35-0.80, P = 0.0039) and to have had at least 10 attacks last
year (OR = 0.51, 95% CI = 0.33-0.80, P = 0.0035). The prescription group was also
more likely to have been admitted to hospital within the last 12 months for asthma or
wheeze (OR = 0.31, 95% CI = 0.16-0.62, P = 0.0009), to use their (3-agonist puffer at
least daily (OR = 0.64, 95% CI = 0.42-0.99, P = 0.0451), and to make more than 25
visits to the pharmacy in the last 12 months to obtain medication (OR = 0.42, 95% CI
= 0.21-0.82, P = 0.0112). There were no significant differences found in the proportion
of people who had ever been admitted to hospital for asthma or wheeze (OR = 0.79,
P = 0.2746) or in those reporting use of P-agonist puffers at least 5 times daily (OR =
0.79 P = 0.4122).

Table 4 shows weighted and crude prevalence estimates of factors related to the
management of adult asthma compared between the OTC group and the prescription
group. The weighted estimates are based upon self reported frequency of pharmacy
visits to obtain anti-asthma medication. The table is also shown in appendix 5 with
weighted estimates based upon frequency of pharmacy visits to have prescriptions
filled for P-agonist drugs. Minimal changes were noted in the prevalence estimates of
the management factors as a result of this methodology.

Table 4: Weighted (and crude) prevalence estimates of factors related to the
management of adult asthma compared between the 'OTC group' and the
'Prescription group'

Total
population

OTC
group

Prescription
group

Crude
odds ratio
(95% CI)

Adjusted
odds ratio
(95% CI)

P
value

objective airways
measurement by the
doctor 'usually' or
'always'

27.9%
(31.1%)

25.4%
(23.4%)
n = 171

32.2%
(35.4%)
n = 308

0.56
(0.360.87)

0.37
(0.210.67)

0.0011

peak flow readings
at home

28.1%
(31.0%)

26.2%
(25.7%)
n = 171

27.8%
(34.0%)
n = 306

0.69
(0.451.08)

0.67
(0.381.17)

0.1597

instruction in inhaler
technique

92.8%
(93.4%)

92.8%
(91.8%)
n = 171

93.3%
(94.2%)
n = 311

0.69
(0.321.51)

0.87
(0.372.01)

0.7407

written action plan

24.7%
(27.8%)

20.5%
(20.5%)
n = 171

27.6%
(31.8%)
n = 311

0.55
(0.350.88)

0.48
(0.260.88)

0.0184

regular medical
review at least once
per year

53.7%
(60.2%)

45.3%
(42.2%)
n = 135

60.7%
(70.3%)
n = 239

0.31
(0.190.49)

0.50
(0.270.93)

0.0297

regular medical
review at least twice
per year

40.3%
(48.4%)

33.6%
(27.4%)
n = 135

47.9%
(60.3%)
n = 239

0.25
(0.150.40)

0.32
(0.170.64)

0.0009

As recommended management depends on disease severity, the crude estimates of
the difference between the OTC and prescription groups were adjusted for the potential
measures of disease severity along with age and sex.

Of the total population, 27.0 per cent (21.7 per cent of the OTC group and 29.8 per cent
of the prescription group) did their own peak flow readings at home.

Of the

respondents 24.9 per cent (18.9 per cent of the OTC group and 28.7 per cent of the
prescription group) had a written action plan. Of the respondents 53.9 per cent (43.2
per cent of the OTC group and 61.1 per cent of the prescription group) reported having
regular medical review at least once per year. Of the respondents 39.7 per cent (25.2
per cent of the OTC group and 48.4 per cent of the prescription group) had regular

medical review at least twice per year.

After adjusting for potential measures of

disease severity, age, and sex, there were significant differences between the OTC
group and the prescription group in regards to; objective airways measurement by the
doctor 'usually' or 'always' (OR = 0.37; 95% CI = 0.21-0.67; P = 0.0011), possession
of a written action plan (OR = 0.48; 95% CI = 0.26-0.88; P = 0.0184), regular medical
review at least once per year (OR = 0.50; 95% CI = 0.27-0.93; P = 0.0297), and regular
medical review at least twice per year (OR = 0.32; 95% CI = 0.17-0.64; P = 0.0009).

The proportion of adult asthmatics who use various medications regulariy ('most of the
time') are presented in Table 5, with the use of medications at any time (those
indicating taking medications 'most of the time' and 'in bad attacks') in the previous six
months presented in Table 6. Again the weighted estimates are based upon the
frequency of pharmacy visits to obtain anti-asthma medication. The results of using
frequency of pharmacy visits to have prescriptions filled for p-agonist drugs as the
basis for the weighting factors are presented in appendix 5. Again only minor
differences were noted between the two weighted estimates.

Table 5: Weighted (and crude) prevalence estimates of the use medications
regularly during the previous six months compared between the 'OTC group'
and the 'Prescription group'

Total
population
n = 483

OTC
group
n = 171

Prescription
group
n = 312

Crude
odds
ratio

Adjusted
odds
ratio
(95% CI)

P
value

inhaled
corticosteroids
or
cromoglycate

55.0
(61.9%)

43.4%
(50.3%)

61.6%
(68.3%)

0.47
(0.310.70)

0.29
(0.160.51)

0.0001

inhaled
corticosteroids

48.8%
(54.2%)

37.9%
(44.4%)

53.9%
(59.6%)

0.54
(0.370.80)

0.35
(0.200.60)

0.0001

cromoglycate

13.4%
(16.4%)

10.8%
(11.7%)

14.6%
(18.9%)

0.57
(0.321.01)

0.67
(0.321.37)

0.2679

ipratropium

10.7%
(17.6%)

4.40%
(5.26%)

14.5%
(24.4%)

0.17
(0.080.37)

0.27
(0.090.88)

0.0289

theophylline

9.58%
(12.8%)

5.07%
(7.02%)

11.7%
(16.0%)

0.40
(0.190.79)

0.30
(0.110.79)

0.0151

oral
corticosteroids

5.81%
(8.70%)

5.30%
(5.85%)

6.20%
(10.3%)

0.54
(0.241.19)

1.45
(0.504.21)

0.4974

antibiotics

15.3%
(15.9%)

9.73%
(11.1%)

18.2%
(18.6%)

0.55
(0.240.88)

0.83
(0.411.70)

0.6118

It is estimated that 55.0 per cent of adult asthmatics (43.4 per cent of the OTC group
and 61.6 per cent of the prescription group) regularly used inhaled preventative
medications (corticosteroids or sodium cromoglycate), and 35.1 per cent have used
antibiotics and 15.3 percent have used antihistamines 'for chest problems' within the
previous six months.

After adjusting for age, sex, and indicators of disease severity the OTC group is less
likely to regularly use inhaled preventative medications (OR = 0.29; 95% CI = 0.160.51; P = 0.0001), inhaled corticosteroids (OR = 0.35; 95% CI = 0.20-0.60; P = 0.0001),
ipratropium (OR = 0.27; 95% CI = 0.09-0.88; P = 0.0289) and theophylline (OR = 0.30;
95% CI = 0.11 -0.79; P = 0.0151). The OTC group is less likely to have used inhaled
corticosteroids (OR = 0.35; 95% CI = 0.21-0.61; P = 0.0002), ipratropium (OR = 0.44;
95% CI = 0.20-0.94; P = 0.0480) and theophylline (OR = 0.43; 95% CI = 0.20-0.94, P
= 0.0348) for chest problems at any time within the previous six months.

Table 6: Weighted (and crude) prevalence estimates of use of medications at
any time during the previous six months compared between the 'OTC group'
and the 'Prescription group'
Total
population
n = 477

OTC
group
n = 171

Prescription
group
n = 306

Crude
odds
ratio
(95%
CI)

Adjusted
odds
ratio
(95% CI)

P
value

inhaled
corticosteroids

55.4%
(60.0%)

47.0
(51.5%)

60.1%
(64.7%)

0.58
(0.390.86)

0.35
(0.210.61)

0.0002

cromoglycate

15.7%
(18.4%)

15.0%
(15.8%)

15.7%
(19.9%)

0.76
(0.451.28)

0.85
(0.431.66)

0.6260

ipratropium

15.5%
(23.0%)

10.4%
(11.1%)

18.4%
(29.5%)

0.30
(0.170.53)

0.44
(0.200.94)

0.0480

theophylline

13.5%
(18.6%)

7.79%
(11.1%)

16.6%
(29.5%)

0.42
(0.240.75)

0.43
(0.200.94)

0.0348

oral
corticosteroids

18.4%
(24.2%)

16.8%
(19.9%)

19.3%
(26.6%)

0.68
(0.421.10)

1.00
(0.521.94)

0.9916

antihistamines

15.3%
(16.8%)

16.1%
(18.7%)

15.4%
(15.7%)

1.24
(0.732.07)

2.76
(1.385.52)

0.0042

antibiotics

35.1%
(38.9%)

31.2%
(32.8%)

37.2%
(42.3%)

0.66
(0.441.00)

1.12
(0.661.88)

0.6791

Due to slight changes in methods of data analysis for the 1995 sample to those
previously reported®®, the results of an identical analysis of the 1991 data are reported
in appendix 4.

5.2 Changes between 1991 and 1995

A comparison between 1991 and 1995 respondents is shown in Table 7 below. There
were no statistically significant differences found between the 1991 and 1995 groups
of respondents in regards to age, sex, asthma diagnosis by doctor, and chronic cough
and sputum. The median age for both 1991 and 1995 respondents was 40 years. The
proportion of those respondents who were male decreased between 1991 and 1995
(53.3 per cent in 1991 to 47.9 per cent in 1995) however this difference was not
statistically significant (OR = 1.24, P = 0.105). The number of respondents that
reported having their asthma diagnosed by a doctor decreased slightly (95.4 per cent
in 1991 to 93.5 per cent in 1995) as did the proportion reporting chronic cough and
sputum (46.2 percent in 1991 to 43.0 percent in 1995) however neither change was
statistically significant.

Table 7: Comparison of 1991 and 1995 respondents
1991

1995

age (years)*

42.1 (40)
n = 419

43.4 (40)
n = 478

sex (M)

53.3%

47.9%

1.24
(0.95-1.63)

0.105

asthma diagnosis
by doctor

95.4%

93.6%

1.41
(0.70-2.87)

0.303

Odds ratio
(95% CI)
-

P value
0.055

46.2%
chronic cough and
1.14
43.0%
0.443
(0.80-1.61)
sputum
* Mean ages reported with median ages in parentheses. Difference tested using a ttest.
There has been a slight but insignificant increase in the proportion of respondents
using a prescription to obtain p-agonist inhalers from 61.2 per cent in 1991 to 64.6 per
cent in 1995 (OR = 1.16, P = 0.243).

The self reported frequency of use of a

prescription to obtain p-agonist inhalers is shown in Table 8.

Table 8: Self reported frequency of prescription use to obtain p-agonist
inhalers compared between 1991 and 1995 respondents.

Use of Prescription

1991

1995

n=:423

n = 483

Never

23.9%

20.5%

Mostly Not

14.9%

14.9%

38.8%

35.4%

Mostly

13.2%

13.5%

Always

48.0%

51.1%

61.2%

64.6%

"Over the counter group"

"Prescription group"

Potential measures of disease severity compared between 1991 and 1995 are shown
in table 9. Slight reductions from 1991 to 1995 were found in the proportion reporting;
wheeze at least once per week, wheeze most or every day, wheeze every day, at least
five attacks of asthma or wheezing last year, at least 10 attacks of asthma or wheezing
last year, hospital admission for asthma or wheezing within the last 12 months and the
use of p-agonist puffers at least daily. In the crude analysis however, none of these
potential disease severity measures had changed significantly. After adjusting for age
and sex, the reduction in the use of p-agonist puffers at least daily from 75.3 per cent
in 1991 to 69.6 percent in 1995 was of marginal significance (OR = 1.08; 95% CI =
1.00-1.16; P = 0.0500).

Table 9: Potential measures of disease severity compared between 1991 and
1995 respondents
1991

1995

Crude odds
ratio
(95% CI)

Adjusted
odds ratio
(95% CI)

P
value

wheeze at least
once per week

78.5%
n = 405

76.7%
n = 477

1.11
(0.80-1.54)

1.04
(0.96-1.13)

0.3618

wheeze most or
every day

63.5%
n = 405

60.8%
n = 477

1.12
(0.84-1.49)

1.04
(0.97-1.11)

0.3038

wheeze every day

29.6%
n = 405

28.9%
n = 477

1.03
(0.77-1.40)

1.02
(0.95-1.10)

0.5365

at least 5 attacks
in the last year

54.0%
n = 422

51.2%
n = 488

1.12
(0.85-1.47)

1.04
(0.97-1.11)

0.2427

at least 10 attacks
in the last year

39.8%
n = 422

36.5%
n = 488

1.15
(0.87-1.52)

1.04
(0.97-1.11)

0.2556

hospital admission
ever for asthma or
wheeze

50.5%
n = 424

54.7%
n = 481

0.84
(0.64-1.11)

0.95
(0.89-1.01)

0.1202

hospital admission
within the last 12
months

14.9%
n = 424

14.1%
n = 481

1.06
(0.72-1.56)

1.01
(0.91-1.10)

0.9247

use of betaagonist puffer at
least once a week

93.8%
n = 417

90.7%
n = 426

1.53
(0.90-2.61)

1.12
(0.98-1.27)

0.0861

use of betaagonist puffer at
least a few times a
week

92.1%
n = 417

86.0%
n = 486

1.89
(1.20-3.00)

1.18
(1.06-1.32)

0.0032

use of betaagonist puffer at
least daily

75.3%
n = 417

69.6%
n = 486

1.33
(0.98-1.81)

1.08
(1.00-1.16)

0.0500

use of betaagonist puffer at
least 5 times daily

15.4%
n = 417

18.3%
n = 486

0.81
(0.56-1.17)

0.95
(0.87-1.04)

0.2632

use of betaagonist puffer
more than 10
times a day

3.84%
n = 471

3.29
n = 486

1.17
(0.55-2.50)

1.04
(0.87-1.25)

0.6814

Various management factors were compared between 1991 and 1995 as shown in
Table 10 below.

Weighted estimates are based on self reported frequency of

pharmacy visits to obtain anti-asthma medications. The prevalence of reporting; peak
flow readings at home increased from 19.5 percent in 1991 to 27.0 percent in 1995
(OR = 0.71, P = 0.022) and the prevalence of reporting regular medical review at least
once per year also increased, from 46.5 per cent in 1991 to 53.9 per cent in 1995 (OR
= 0.71, P = 0.024). After adjusting for potential measures of disease seventy, age and
sex, the differences were not statistically significant for both peak flow readings at
home (OR = 0.94; 95% CI = 0.86-1.03; P = 0.2060) and regular medical review at least
once per year (OR = 0.92; 95% CI = 0.83-1.02; P = 0.1127) or for any of the other nonmedication related management factors.

Table 10: Weighted (and crude) prevalence estimates of factors related to the
management of adult asthma compared between the 1991 and 1995
respondents

1991

1995

Crude
odds ratio
(95% CI)

Adjusted
odds ratio
(95% CI)

P
value

objective airways
measurements by the
doctor 'usually' or
'always'

24.1%
(28.2%)
n = 422

28.4%
(31.4%)
n = 487

0.86
(0.64-1.15)

0.96
(0.88-1.05)

0.4036

peak flow readings at
home

19.5%
(24.5%)
n = 421

27.0%
(31.3%)
n = 485

0.71
(0.52-0.96)

0.94
(0.86-1.03)

0.2060

instruction in inhaler
technique

89.6%
(91.9%)
n = 421

90.9%
(93.1%)
n = 490

0.85
(0.50-1.43)

1.02
(0.88-1.18)

0.7658

written action plan

18.4%
(22.8%)
n = 417

24.9%
(27.6%)
n = 490

0.78
(0.57-1.06)

0.97
(0.89-1.07)

0.5807

regular medical review
at least once per year

46.5%
(51.6%)
n = 314

53.9%
(60.2%)
n = 379

0.71
(0.52-0.97)

0.92
(0.83-1.02)

0.1127

regular medical review
at least twice per year

36.2%
(43.3%)
n = 314

39.7%
(48.6%)
n = 379

0.81
(0.59-1.11)

0.94
(0.84-1.04)

0.2119

A Gomparison between 1991 and 1995 of the regular use of various medications is
shown in Table 11, with use at any time shown in Table 12. Again weighted estimates
are based on frequency of pharmacy visits for anti-asthma medications. The proportion
of respondents using inhaled corticosteroids increased from 39.3 percent in 1991 to
48.0 per cent in 1995 (OR = 0.90, 95% CI = 0.83-0.98, P = 0.016) and use of sodium
cromoglycate has increased from 9.12 per cent to 13.4 per cent in 1995 (OR = 0.82,
95% CI = 0.73-0.93, P = 0.0015). The proportion of respondents reporting use of
theophyllines decreased from 19.0 per cent in 1991 to 9.58 per cent in 1995 (OR =
1.27, 95% CI = 1.14-1.41, P = 0.0001).

Table 11: Weighted (and crude) prevalence estimates of the use of
medications regularly during the previous six months compared between 1991
and 1995 respondents

1991
n = 421

1995
n = 491

Crude odds
ratio
(95% CI)

Adjusted
odds ratio
(95% CI)

P value

inhaled
corticosteroids or
cromoglycate

43.7%
(51.1%)

55.0%
(62.1%)

0.64
(0.48-0.83)

0.87
(0.80-0.95)

0.0019

inhaled
corticosteroids

39.3%
(46.4%)

48.0%
(54.4%)

0.73
(0.55-0.95)

0.90
(0.83-0.98)

0.0160

cromoglycate

9.12%
(10.5%)

13.4%
(16.7%)

0.58
(0.39-0.88)

0.82
(0.73-0.93)

0.0015

ipratropium

9.14%
(14.0%)

10.7%
(17.5%)

0.77
(0.53-1.11)

0.91
(0.81-1.03)

0.1542

theophylline

19.0%
(24.2%)

9.58%
(13.0%)

2.13
(1.49-3.05)

1.27
(1.14-1.41)

0.0001

oral
corticosteroids

6.00%
(8.39%)

5.81%
(8.76%)

0.95
(0.59-1.55)

0.98
(0.86-1.13)

0.7894

antibiotics

16.0%
(15.2%)

15.3%
(16.3%)

0.92
(0.63-1.33)

1.01
(0.91-1.13)

0.8277

No significant changes were found in the regular use or the use at any time of
ipratropium, oral corticosteroids, antihistamines and antibiotics in the previous six
months.

Table 12: Weighted (and crude) prevalence estimates of the use of
medications at any time (regularly and/or during bad attacks) compared
between 1991 and 1995 respondents

1991
n = 421

1995
n = 491

Crude odds
ratio
(95% CI)

Adjusted adds
ratio
(95% CI)

P
value

inhaled
corticosteroids

47.0%
(54.6%)

55.4%
(60.1%)

0.80
(0.61-1.05)

0.94
(0.86-1.02)

0.1392

cromoglycate

11.2%
(13.5%)

13.5%
(18.7%)

0.68
(0.47-0.98)

0.87
(0.77-0.97)

0.0117

ipratropium

13.9%
(20.3%)

15.5%
(23.0%)

0.85
(0.61-1.18)

0.95
(0.86-1.06)

0.3901

theophylline

25.8%
(32.6%)

13.5%
(18.7%)

2.10
(1.53-2.88)

1.27
(1.15-1.40)

0.0001

oral
corticosteroids

15.4%
(21.7%)

18.4%
(24.2%)

0.87
(0.63-1.19)

0.99
(0.90-1.09)

0.8559

antihistamines

12.9%
(13.5%)

15.3%
(16.7%)

0.78
(0.53-1.14)

0.93
(0.83-1.04)

0.2012

antibiotics

35.0%
(36.8%)

35.1%
(39.1%)

0.91
(0.69-1.20)

0.99
(0.91-1.07)

0.7975

6. STUDY LIMITATIONS

The repeated cross-sectional study design is limited in that there are no control areas
to determine whether local or national Initiatives have had any affect. The study cannot
be generalised to an area outside of the lllawarra region of New South Wales.

Although there was an attempt to exclude those with chronic bronchitis in the Pharmacy
Exit Survey, there may still be some in the study population of both the Drug Utilisation
Survey and the Pharmacy Exit Survey. The criteria which was used to exclude people
with chronic bronchitis should keep the numbers small. It is possible that those people
with very mild asthma would not make it into the sample due to their infrequent need
to visit a pharmacy. Some mild asthmatics may not actually be using drug therapy and
hence not visit a pharmacy at all.

Although prevalence estimates of management indicators were weighted in an attempt
to adjust for the fact that more severe asthmatics would visit community pharmacies
more frequently, it is possible that disease severity has still not been adequately
adjusted for.

Although pharmacists were specifically requested to approach consecutive clients in
the Pharmacy Exit Survey, there was no means of assuring this. It is possible that
pharmacists may not have actually recorded all non-responders which would increase
the response rate. Where there was more than one pharmacist working at a particular
pharmacy, it is not known whether consecutive clients were approached by just one
pharmacist or by all pharmacists at the pharmacy. This may be relevant where certain
pharmacists may work set shifts which may service customers with different
characteristics. It is also not known whether just pharmacists or pharmacy assistants
were involved in administering the survey.

Although a reliability check was made on the questionnaire in 1991, the questionnaire
has not been validated, except for the initial questions relating to asthma diagnosis and

chronic cough and sputum which were recorded on the pharmacists data sheet.
None of the measures of disease severity used in the Pharmacy Exit Survey were
objective and ail were self-reported. The measurement of whether respondents have
asthma, although previously validated is still a subjective measure.
Although most questions from the Pharmacy Exit Survey questionnaire had a very high
rate of completeness, the question relating to respondents visiting the doctor about
their chest were not answered by as many respondents as the rest of the questionnaire.
The questionnaire was also affected by some minor wording changes in 1995. These
changes are not expected to significantly alter the respondents interpretation of those
questions affected.

The Dmg Utilisation Survey also possibly suffers selection bias due to the non-random
selection of pharmacies to be involved in the study. The work involved in providing the
information from the pharmacy databases is extensive and very time consuming and
hence only those pharmacists who were interested in asthma were asked to participate.
Another issue in the Drug Utilisation Survey is the extent of passing trade which was
received by pharmacies. In 1995, the participating pharmacies were considered to be
affected little by passing trade. The smaller the amount of passing trade, the higher the
quality of information relating to asthma sufferers prescribed medication use.

There are a number of deficiencies with the methodology used to control for the likely
oversampling of more severe asthmatics visiting community pharmacies more
frequently to obtain anti-asthma medications. Firstly the data collected in the Drug
Utilisation Survey is limited to prescribed anti-asthma medications and does not include
those customers purchasing beta-agonist inhalers over the counter. The corresponding
question in the Pharmacy Exit Survey which was used both in 1991 and 1995 refers to
pharmacy visits to obtain medication for the chest. In 1995 the more appropriate
question 13 was added to the Pharmacy Exit Survey which referred specifically to

pharmacy visits to have prescriptions filled for beta-agonist drugs. In order to compare
between 1991 and 1995, the first less appropriate question had to be used to weight
the prevalence estimates of management factors. Nevertheless, as discussed in the
results, it is reassuring that the estimate did not differ appreciably depending on which
question was used to derive the weighting factor for the 1995 data.
Secondly, the data able to be obtained on age from the Drug Utilisation Survey was
limited and hence some of those aged less than 15 years are included in the sample.
In the Pharmacy Exit Survey, pharmacists were instructed to only administer the
questionnaire to customers who were 15 years of age and over. Some aged less than
15 years were surveyed, however more complete data on age allowed their exclusion
from the sample. Therefore the two sample populations differ in that the Pharmacy Exit
Survey includes those purchasing beta-agonist inhalers over the counter whereas the
Drug Utilisation Survey only includes data on prescriptions, and the Drug Utilisation
Survey possibly includes some individuals aged less than 15 years.
Because only people obtaining their medication by prescription were sampled in the
Dnjg Utilisation Survey, mild asthmatics would have been under-represented in these
data.

This is another reason why it is likely that the prevalence estimate of

management factors have not adequately adjusted for the over-representation of more
severe asthmatics.

7. DISCUSSION

The group predominantly obtaining their P-agonists over the counter is younger, more
likely to be male, and less likely to report chronic cough and sputum. Males are less
likely to go to the doctor than females®\ and hence less likely to obtain a script. There
are quite large financial benefits from obtaining various anti-asthma medications on
prescription rather than over the counter for those people holding a concession card.
P-agonists can be obtained for around a quarter of the price if a script and concession
card is used. Holders of concession cards are generally older and hence use a script
in order to obtain the financial benefits. Older people are also more likely to visit a
general practitioner for problems other than asthma and may obtain scripts for antiasthma medications on the same visit.

Although there has only been a statistically insignificant increase in the proportion of
respondents mainly obtaining their p-agonists by prescription, it is similar to the
increase noted in a similar study in the Hunter Valley region of NSW in 1989.®^ It is
unlikely that there would be an increase in the proportion using a prescription to obtain
P-agonist inhalers without an increase in the proportion of people having routine
medical review.

In 1991, the only difference in potential disease severity indicators between the OTC
group and the prescription group were in hospital admissions for asthma or wheeze.
In 1995 the differences between the OTC group and the prescription group were more
prominent with regards to disease severity with the prescription group more likely to
wheeze at least once per week, wheeze most or every day, have at least 5 attacks of
asthma or wheeze in the last year, have at least 10 attacks of asthma or wheeze in the
last year, to be admitted to hospital within the last 12 months for asthma or wheeze and
to use a p-agonist inhaler at least daily. These differences were evident both in the
crude analysis and after adjusting for age and sex. This suggests that the gap between
the OTC group and the prescription group with regards to disease severity may be
widening. More severe cases of asthma are more likely to be prescribed preventative

drugs which are only available by prescription and obtain their p-agonists prescriptions
at the same time.
As in 1991, in 1995 the OTC group was significantly less likely, both in crude and
adjusted analysis, to have objective airways measurement by the doctor 'usually' or
'always' (OR = 0.37; 95% CI = 0.21-0.667; P = 0.0011), regular medical review at least
once per year (OR = 0.50; 95% CI = 0.27-0.93; P = 0.0297) and regular medical review
at least twice per year (OR = 0.32; 95% CI = 0.17-0.64; P = 0.0009). In 1995 there was
an additional difference between the OTC group and the prescription group in that the
prescription group were more likely to have a written action plan of what to do in an
attack (OR = 0.48; 95% CI = 0.26=0.88; P = 0.0184). This difference may also be
related to improved management by general practitioners.

The National Asthma

Strategy Goals and Targets set by the National Asthma Campaign aimed for 21 per
cent of people to have a written action plan by the year 2000. The baseline for this
target is 14 per cent of adults with a written action plan.®^ A repeat of this survey in
1993 found the proportion of people with a written action plan to be 19.9 per cent.^
Therefore it can be seen that the lllawarra in 1995 had a reasonably good proportion
of adults with written action plans (24.9 per cent) and the magnitude of the
improvement since 1991 was similar to the National Asthma Campaign survey
completed slightly earlier. The National Asthma Campaign sampling method was very
different from that of the lllawarra survey. The National Asthma Campaign survey
sampled parents of a random sample of primary schoolchildren from Sydney,
Melbourne, Brisbane and the Upper Hunter Valley (New South Wales).

It is also

possible that the weighting method used here in the lllawarra sample does not
adequately adjust for the oversampling of people with more severe asthma.

The proportion of the respondents reporting objective airways measurement by the
doctor 'usually' or 'always' (28.4 per cent) and measurement of peak flow at home (27.0
percent) were still low in 1995. The National Asthma Campaign survey reported that
in 1993, 29.9 per cent of adult asthmatics had a peak flow meter and 44.4 per cent had
their lung function measured by the doctor in the previous year.

There has been considerable debate recently as to whether frequency of p-agonist
medication use is an indication of disease severity or of management.

Logistic

regression analysis was run without including frequency of [B-agonist use as a potential
confounder in analyses related to asthma management. The results are presented in
appendix 6.

Minimal changes were observed in the odds ratio estimates for the

management indicators, and therefore the use of P-agonists is not considered to be a
significant confounder of asthma management here.
In 1991 there was a significant difference between the OTC group and the prescription
group in the reported regular use of oral corticosteroids, however in 1995, this
difference was not evident. The opposite is the case with the use of theophylline which
showed no significant difference between the OTC group and the prescription group
in 1991, however in 1995 the difference is significant at the 0.05 level (OR = 0.30; 95%
CI = 0.11-0.79; P = 0.0151). This difference was also noted in the use of theophylline
at any time (OR = 0.43; 95% CI = 0.20-0.94; P = 0.0348). This is a positive result as
the Asthma Management Plan recommends close supervision of the use of
theophylline.^ Overall, regular theophylline use decreased from 19.0 percent to 9.6
per cent. This reduction in the use of theophyllines is not as great as that seen in the
second evaluation survey done for the National Asthma Campaign. They report a
significant reduction in theophylline use from 20.5 percent in 1990 to 3.9 percent in
1993.®® Again it is possible that the weighting method used in the lllawarra survey has
not adequately adjusted for an oversampling of people with more severe disease.
Differences were found in regular use of inhaled corticosteroids and ipratropium
between the 'over the counter' group and the prescription group both in 1991 and 1995.

While there were slight improvements in most indicators of disease severity between
1991 and 1995, these changes were not significant except in relation to the frequency
of use of p-agonist inhalers. Reductions in the proportion of people using p-agonist
inhalers between at least a few times a week and at least daily suggest improved
disease severity and/or asthma management. Changes in prescribing which have
been made are in accordance with the Asthma Management Plan with increased

prescribing of inhaled corticosteroids and a reduction in the reliance on regular use of
P-agonist inhalers.

These changes have occurred in those people who have a

moderate (between a few times a week and four times a day) usage of (3-agonist
inhalers rather than those with a very high (more than 5 times a day) usage of P-agonist
inhalers.
While most non-medication related management indicators improved slightly between
1991 and 1995, these changes were not significant. This is possibly due to a lack of
statistical power and/or that the emphasis of the asthma management plan and local
initiatives has been on better prescribing. The proportion of people having regular
medical review even when their chest is not causing problems is probably higher than
previously thought. Westley-Wise et al reported 38.1 per cent of those responding to
the 1991 pharmacy exit survey having regular medical review at least once per year,
and 32.1 per cent at least twice per year.®^ The corresponding proportions for the
reanalysis of the 1991 pharmacy exit survey were 51.6 per cent and 43.3 per cent
which are significantly higher. The initial analysis by Westley-Wise ei a/assumed
non-respondents to this question did not have regular medical review. Results of the
1991 reanalysis are presented in full in appendix 4.

There has undoubtedly been an improvement in the prescribing of anti-asthma drugs
in the lllawarra between 1991 and 1995. Significant improvements in the regular use
of either inhaled corticosteroids or cromoglycate and a dramatic decrease in use of
theophylline indicates changes in prescribing in line with the recommendations of the
asthma management plan. The changes in preventative maintenance therapy have not
been as great as those put forward in the National Asthma Campaign goals and targets
document.

The target is for 80 per cent of the adult asthmatic population to use

preventative maintenance therapy by 1996, based upon a baseline measure of 39 per
cent in 1990.^ The National Asthma Campaign survey reported 38 per cent using
inhaled corticosteroids or sodium cromoglycate in 1990. This increased to 43 per cent
by 1993.®® The increase in the lllawarra from 44 percent in 1991 to 55 per cent in 1995
suggests a higher baseline and a greater increase in the lllawarra, however this may

reflect the different surveillance methods used for the national and lllawarra estimates.
This increase was significant after adjusting for age, sex and potential measures of
disease severity (OR = 0.87; 95% CI = 0.80-0.95; P = 0.0019).

8. CONCLUSIONS AND RECOMMENDATIONS

Prescribing changes are evident through increases in the proportion of respondents
who are using preventative medications and a decrease in the use of theophyllines.
These change are in line with those recommended by the asthma management plan.
Changes in non-dmg related asthma management factors were minor. This is possibly
due to the emphasis which has been placed on improved drug management, or the
failure of non-drug asthma management education to reach the target audience. There
is some suggestion that that asthma severity may have improved slightly between 1991
and 1995 which may be associated with an increase in use of preventative medications
and a slight decline in frequent p-agonist use.

The increased distinction in disease severity and asthma management indicators
between the OTC group and the prescription group emphasises the importance of
regular medical consultation and supervised asthma management. The problem of
asthma sufferers not having regulair medical review should be adequately addressed
through the recent introduction of the asthma card throughout the lllawarra.

The

asthma card aims to monitor unsupen/ised (3-agonist use and encourages users to have
routine medical review of asthma.

A coherent strategy involving as many lllawarra general practitioners and pharmacists
as possible is recommended. Improved asthma management should be promoted with
an emphasis on non-pharmacological issues such as the use of written action plans,
peak expiratory flow measurement, and regular medical review.

Previous local

initiatives have only involved a small sample of interested lllawarra general
practitioners.

A concentrated local program with the above aims is needed to

complement the strategies of the National Asthma Campaign.

The usefulness of the Pharmacy Exit Survey and the Drug Utilisation Survey is shown
in this study and in order to evaluate the introduction of the asthma card in the lllawarra
and other strategies presently being prepared, these surveys should again be repeated
in 1999. The use of pharmacies for sample recruitment has produced excellent results
and should continue to be used to monitor adult asthma management in the lllawarra.
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ABSTRACT

Objective: To describe recent trends in adult asthma management and to compare
between groups primarily obtaining p-agonist inhalers 'over the counter' (the OTC
group) and by prescription (the prescription group).
Setting: Consecutive clients of community pharmacies in the lllawarra purchasing antiasthmatic medications.
Design: Repeated cross-sectional surveys of adults (aged 15 years and over) in 1991
and 1995. Data from a second study of drug prescriptions dispensed by community
pharmacies were used to determine prevalence estimates of various asthma
management indicators for a population of adults with asthma.
Results: P-agonist inhalers were primarily obtained over the counter by 35.4 per cent
of respondents. The prescription group reported more severe disease than the OTC
group.

After taking into account differences between the two groups in disease

severity, age and sex the OTC group was less likely to use either inhaled
corticosteroids or sodium cromoglycate (OR=0.29, Cl=0.16-0.51), or ipratropium
bromide (OR=0.27, CI=0.09-0.88) regularly during the previous six months, and less
likely to have used inhaled corticosteroids (OR=0.15, Cl=0.21-0.61), and ipratropium
bromide (OR=0.44, CI=0.20-0.94) at any time. The OTC group was also less likely to
have routine medical review at least once per year (OR=0.50, CI=0.27-0.97), have their
airways objectively measured by the doctor usually or always (OR=0.37, Cl=0.21 -0.67)
and to have a written action plan (OR=0.48, CI=0.26-0.88). No significant improvement
in non-drug related asthma management indicators between 1991 and 1995 was
evident. However, prescribing patterns improved with increases in the regular use of

inhaled corticosteroids or sodium cromoglycate and a reduction in the use of
theophylline. It is estimated that 55.0 per cent of adults with asthma now use inhaled
preventative medications regularly, 24.9 percent have written action plans, and 53.7
per cent have routine medical review at least once per year.
Conclusions: Improvements in asthma management are sub-optimal, particularly for
people who primarily obtain their P-agonist inhalers over the counter. The recent
introduction of the 'Asthma Card' in the lllawarra should address some of these issues.

INTRQDUnTION

The National Asthma Campaign (NAC) began in 1989 with the aim of improving the
management of asthma through the promotion of a recognised 'Asthma Management
Plan'.^ The Asthma Management Plan draws on evidence that many asthma deaths
are associated with undertreatment related to an over-reliance on bronchodilator
medication and underuse of inhaled and oral corticosteroids, failure to make objective
measurement of disease severity and inadequate supervision.^-^ "^®
' ® Up to two thirds of
all asthma deaths may be associated with preventable factors^ and with currently
available medication, morbidity from asthma can be reduced.® The first phase of the
NAC was aimed at health professionals, and included mail-outs and advertisements in
frequently read medical journals promoting the asthma management plan.® The second
and third phases of the campaign promoted increased awareness to the asthma
sufferer and the general community respectively.^®

In 1991 the lllawarra Pharmacists Association in conjunction with the lllawarra Area
Health Service and the University of Wollongong Department of Mathematics undertook
the a survey of adult asthma management amoung people obtaining their medication
from community pharmacies in the lllawarra.

This survey was repeated in 1995

allowing evaluation of improvement in adult asthma management over this time period,
as a result of both national and local initiatives.

Respondents predominantly obtaining their medications by prescription in the 1991
Pharmacy Exit Survey were managed better than those primarily purchasing their IBagonist inhalers over the counter, however the management of both groups was sub-

optimal.^^ Reported here are current levels of asthma management described in terms
of the National Asthma Campaign recommendations. Those management indicators
are compared between those predominantly obtaining their p-agonist inhalers by
prescription and those primarily purchasing them over the counter as well as analysing
changes between 1991 and 1995. Crude prevalence estimates of asthma management
factors were weighted using data from another study of asthma drug prescriptions in
an attempt to adjust for the potential bias from an oversampling of those who purchase
their medications more frequently. .

METHODS

The same survey methodology was used in 1995 as in 1991, except for slight changes
to the questionnaire, and small differences in the methods of analysis from the original
study.""^ All pharmacies (66) in the lllawarra area were asked to participatein both 1991
and 1995. Each pharmacist was asked to recruit 12 consecutive clients aged 15 years
or over obtaining any anti-asthmatic medications (3-agonists, theophyllines, inhaled
corticosteroids, ipratropium, or sodium cromoglycate) to fill in the one page
questionnaire. Each pharmacist completed a data sheet including: the gender and age
(estimated for non-responders); their answers to two questions derived from a
previously validated questionnaire^^ (concerned with previous asthma diagnosis and
chronic sputum production); and whether they agreed or refused to complete the
questionnaire. The questions concerned with sputum production and asthma diagnosis
were used to exclude people with chronic bronchitis (defined as reporting chronic
sputum production and never been diagnosed with asthma) at the data analysis stage.

The questionnaires include questions related to asthma management practices such
as use of peak flow meters, written plans, medication, and medical supervision. Also
included were questions related to asthma severity such as frequency of wheezing and
"attacks" of asthma and wheeze, previous hospitalisation, and frequency (3-agonist
inhaler use. In addition two questions concerned the frequency of visits to community
pharmacies to obtain anti-asthma medications and to have scripts filled for p-agonists.

The data were entered into Epilnfo v5.1 and analysed using SAS v6.10 for Windows.
Prevalence estimates were made of indicators related to asthma severity and asthma

management.

Crude odds ratios were used to compare severity and asthma

management indicators between groups who reported mainly obtaining p-agonists over
the counter or mainly by prescription in 1995 and between the 1991 and 1995 groups.
Statistical significance was established by means of the chisquared test. Confidence
limits of the crude odds ratios were calculated by the methods of Cornfield using
Epilnfo v6.0.

The crude odds ratios for potential measures of disease severity were adjusted for age
and sex by logistic regression analysis. The crude odds ratios for asthma management
factors were adjusted for age, sex and indicators of disease severity using stepwise
logistic regression analysis. Indicators of disease severity were frequency of wheezing
(categorised as at least weekly, at least most days, and at least daily), frequency of
asthma attacks (categorised as at least five and at least 10 in the last year), frequency
of pharmacy visits to obtain "chest" medication (categorised as at least once in the last
12 months, at least 3-4 times, at least 5-10 times, at least 11-25 times and more than
25 times), previous hospitalisation (characterised as ever and within the last year), and
frequency of inhaler use (characterised as at least once a week, a few times per week,
once a day, five times a day, and more than ten times a day). The logistic regression
analysis were also run without including frequency of inhaler use as a potential
confounder, however the results were essentially unchanged. Statistical significance
will be shown at the 0.05 level with 95 per cent confidence limits.

In order to adjust prevalence estimates of asthma management factors for the potential
bias from an oversampling of those who purchase their asthma medications more
frequently, crude weighting factors were devised based on the reported frequency of

pharmacy visits. Estimates were made of the proportions of the asthmatic population
visiting pharmacies on various numbers of occasions in the previous year , using
patient profiles developed in a second study utilising routinely collected drug
prescription information. These methods have been described e l s e w h e r e . T w o
different weighting factors were devised.

The first was based on frequency of

pharmacy visits to obtain anti-asthma medication and the second on frequency of
pharmacy visits to have prescriptions filled for (B-agonist drugs. The weighting factors
were calculated by dividing the population distribution (using the patient profile) by the
sample distributions (using the questionnaire survey data).

RESULTS

1995 Pharmacy Exit Survey

Six hundred and eighty three purchasers of anti-asthma medications aged 15 years and
over were asked to fill in the one page written questionnaire. Of these 507 agreed
giving a response rate of 74.2 percent. Eighteen respondents reported chronic sputum
production without being diagnosed with asthma and were excluded from further
analysis.

The median age of the respondents was 40 years with 47.9 per cent being male
compared with 36 years and 53.8 per cent respectively for non-respondents. Ninety
per cent of respondents had been diagnosed with asthma by a doctor compared with
86 per cent of non-respondents. Forty three per cent of respondents and 40.5 per cent
of non-respondents reported chronic sputum production. The proportion of nonrespondents obtaining their p-agonist inhalers over the counter on this occasion was
55.6 per cent compared with 40.2 per cent of respondents. Of the respondents 20.5
per cent reported that they always, and a further 14.9 per cent reported that they
usually obtained their P-agonist medications over the counter, while 51.1 per cent
indicated that they always and 13.5 per cent usually used a prescription to obtain their
p-agonist medication.

The respondents were more likely to have had their asthma diagnosed by a doctor (OR
= 2.09, P = 0.022) and less likely to have obtained their anti-asthma medication 'over
the counter' on this occasion (OR = 0.54, P = 0.00082). There was no significant

difference between the respondents and non-respondents in age (P = 0.055), the
proportion of males (OR = 0.79, P = 0.186), nor the proportion who reported chronic
cough and sputum (OR = 0.93, P = 0.741).

Respondent classification as either mainly obtaining their anti-asthmatic medications
over the counter (the OTC group) or by prescription (the prescription group) was based
upon their self reported frequency of using a doctors prescription to obtain (3-agonist
inhalers. Of the 507 respondents 35.4 per cent reported never (20.5 per cent) or
mostly not (14.9 per cent) using a prescription to obtain inhalers. These respondents
were classified as mainly obtaining inhalers over the counter. Of the respondents 64.6
percent reported mostly (13.5 per cent) or always (51.1 per cent) using a prescription
to obtain inhalers and were hence categorised as mainly obtaining their inhalers by
prescription.

A comparison of those respondents predominantly obtaining their |3-agonist inhalers
over the counter and those using a prescription is shown in Table 1. The OTC group
was (using at-test) older (P = 0.001), more predominantly male (OR = 1.74, P = 0.004),
and less likely to report chronic cough and sputum (OR = 0.52, P = 0.006) than the
prescription group.

There was no difference found in the proportion having asthma

diagnosed by the doctor (OR = 0.98, P = 0.956).

Of the respondents 69.6 percent reported at least daily use of their p-agonist inhalers
and 18.1 percent at least five times daily use, 60.6 percent reported wheezing at least
most days and 28.5 per cent every day, 51.0 per cent reported at least five attacks
within the previous twelve months and 36.5 per cent reported at least ten attacks. Of

the respondents 55.0 percent had been admitted to hospital with 'asthma' or'wheeze'
at least once previously and 13.7 per cent were admitted within the previous year.

These potential measures of disease severity were compared between the two groups
(Table 2). The OTC group was less likely to report wheezing at least once per week
(OR = 0.59; 95% CI = 0.39-0.96; P = 0.0320) as well as at least most days (OR = 0.55;
95% 01 = 0.36-0.84; P = 0.0052). In the crude analysis, the OTC group was less likely
to report wheezing every day (OR = 0.52, P = 0.004) however after adjusting for
differences in age and sex, this difference was not significant (OR = 0.66, 95% CI =
0.40-1.07; P = 0.0945).

The prescription group was more likely to have had at least 5 attacks in the last year
(OR = 0.47, P = 0.001) and to have had at least 10 attacks in the last year (OR = 0.47,
P = 0.0035). The prescription group was also more likely to have been admitted to
hospital within the last 12 months for asthma or wheeze (OR = 0.31, P = 0.0009), to use
their p-agonist puffer at least daily (OR = 0.64, P = 0.0451), and to make more than 25
visits to the pharmacy in the last 12 months to obtain medication (OR = 0.42, P =
0.0112). There were no significant differences found in the proportion of people who
had ever been admitted to hospital for asthma or wheeze (OR = 0.79, P = 0.2746) or
in those reporting use of (3-agonist puffers at least 5 times daily (OR = 0.79, P =
0.4122).

Weighted and crude prevalence estimates of factors related to the management of
adult asthma for the total population and compared between the OTC group and the
prescription group are shown in Table 3.

The OTC group was less likely to have; objective airways measurement by the doctor
'usually' or 'always' (OR = 0.37; 95% CI = 0.21-0.67; P = 0.0011), possession of a
written action plan (OR = 0.48; 95% CI = 0.26-0.88; P = 0.0184), regular medical review
at least once per year (OR = 0.50; 95% CI = 0.27-0.93; P = 0.0297), and regular
medical review at least twice per year (OR = 0.32; 95% CI = 0.17-0.64; P = 0.0009).

The proportion of adult asthmatics who use various medications are presented in Table
4. It is estimated thet 55.0 per cent regularly used inhaled preventative medications
(corticosteroids or sodium cromoglycate), 10.7 per cent regularly used ipratropium
bromide, and 9.58 per cent regularly use theophylline.

An estimated 5.81 cent

regularly use oral corticosteroids. Antibiotics were regularly used by 15.3 per cent of
respondents.

The OTC group was less likely to regularly use inhaled preventative medications (OR
= 0.29; 95% CI = 0.16-0.51; P = 0.0001), inhaled corticosteroids (Adjusted OR = 0.35;
95% CI = 0.20-0.60; P = 0.0001), ipratropium (OR = 0.27; 95% CI = 0.09-0.88; P =
0.0289) and theophylline (OR = 0.30; 95% CI = 0.11-0.79; P = 0.0151). The OTC
group was also less likely to have used inhaled corticosteroids (OR = 0.35; 95% CI =
0.21-0.61; P = 0.0002), ipratropium (OR = 0.44; 95% CI = 0.20-0.94; P = 0.0480) and
theophylline (OR = 0.43; 95% CI = 0.20-0.94, P = 0.0348) for chest problems at any
time within the previous six months.

Changes between 1991 and 1995

There was a slight but insignificant increase in the proportion of respondents using a
prescription to obtain p-agonist inhalers from 61.2 per cent in 1991 to 64.6 per cent in
1995. The 1991 and 1995 respondents were similar in terms of age, sex, proportion
reporting asthma diagnosis by doctor and chronic cough and sputum for at least three
months continually.

The decline in use of p-agonist puffers at least daily from 75.3 per cent in 1991 to 69.6
per cent in 1995 was of marginal significance (OR = 10.8; 95% CI = 1.00-1.16; P =
0.0500). Slight reductions were noted on frequency of wheezing, frequency of attacks
of asthma or wheeze, and in hospital admission within the last 12 months, however
these improvements were not statistically significant.

Various non-drug management factors were compared between 1991 and 1995 as
shown in Table 5. After adjusting for potential measures of disease severity, age and
sex, the differences between 1991 and 1995 were not statistically significant.

A comparison between 1991 and 1995 of the use of various medications is shown in
Table 6. After adjusting for age, sex, and potential measures of disease severity,
differences in use of inhaled corticosteroids, sodium cromoglycate and theophyllines
were significant at the 0.05 level. Between 1991 and 1995 it is estimated that regular
use of inhaled preventative medications increased from 44 per cent to 55 per cent and
regular use of theophylline declined from 19.0 per cent in 1991 to 9.58 per cent in
1995.

No significant clianges were found in the regular use or the use at any time of
ipratropium, oral corticosteroids, and antibiotics in the previous six months.

DISCUSSION

The group predominantly obtaining their 3-agonists over the counter is younger, more
likely to be male, and less likely to report chronic cough and sputum. Males are less
likely to go to the doctor than females^^ and hence less likely to obtain a script. There
are quite large financial benefits from obtaining various anti-asthma medications on
prescription rather than over the counter for those people holding a concession card.
3-agonists can be obtained for around a quarter of the price if a script and concession
card is used. Holders of concession cards are generally older and hence use a script
in order to obtain the financial benefits. Older people are also more likely to visit a
general practitioner for problems other than asthma and may obtain scripts for antiasthma medications on the same visit.

The proportion of respondents mainly obtaining their p-agonists by prescription, it is
similar to the increase noted in a similar study in the Hunter Valley region of NSW in
1989."'® This group does not have routine review of their asthma as often as the
prescription group, and are less likely to have a written action plan. It is unlikely that
there would be an increase in the proportion using a prescription to obtain P-agonist
inhalers without an increase in the proportion of people having routine medical review..

In 1991, the only significant difference in potential disease severity indicators between
the OTC group and the prescription group were in hospital admissions for asthma or
wheeze, in 1995 the differences between the OTC group and the prescription group
were more prominent with regards to disease severity with the prescription group more
likely to wheeze at least once per week, wheeze most or every day, have at least 5

attacks of asthma or wheeze in the last year, have at least 10 attacks of asthma or
wheeze in the last year, to be admitted to hospital within the last 12 months for asthma
or wheeze and to use a p-agonist inhaler at least daily. These differences were evident
both in the crude analysis and after adjusting for age and sex. This suggests that the
gap between the OTC group and the prescription group with regards to disease
severity may be widening.
The prescription group has better asthma management practices particularly in relation
to objective measurement by the doctor, routine medical review, and use of a written
action plan. The National Asthma Strategy Goals and Targets set by the National
Asthma Campaign aimed for 21 per cent of people to have a written action plan by the
year 2000. The baseline for this target is 14 per cent of adults with a written action
plan."*^ A repeat of this survey in 1993 found the proportion of people with a written
action plan to be 19.9 per cent.^® Therefore it can be seen that the lllawarra in 1995
had a reasonably good proportion of adults with written action plans (24.9 per cent) and
the magnitude of the improvement since 1991 was similar to the National Asthma
Campaign survey completed slightly earlier. The NAC sampling method was very
different from that of the lllawarra survey. The NAC survey sampled parents of a
random sample of primary schoolchildren. It is also possible that the weighting method
used here in the lllawarra sample does not adequately adjust for the oversampling of
people with more severe asthma in the OTC group. This methodology is appropriate
for the prescription group as the weighting factors were developed from prescription
data.

The proportion of the respondents reporting objective airways measurement by the
doctor 'usually' or 'always' (28.4 per cent) and measurement of peak flow at home (27.0
percent) were still low in 1995. The National Asthma Campaign survey reported that
in 1993, 29.9 per cent of adult asthmatics had a peak flow meter and 44.4 per cent had
their lung function measured by the doctor in the previous year.

The prescription group was more likely to use theophylline at any time in the previous
six months (OR = 0.43; 95% CI = 0.20-0.94; P = 0.0343). This is a positive result as
the unsupervised use of theophylline drugs is considered poor management. Overall,
regular theophylline use decreased from 19.0 percent to 9.6 percent. This reduction
in the use of theophyllines is not as great as that seen in the second evaluation survey
done for the National Asthma Campaign.

They report a significant reduction in

theophylline use from 20.5 per cent in 1990 to 3.9 per cent in 1993.^® Differences were
found in regular use of inhaled corticosteroids and ipratropium between the 'over the
counter' group and the prescription group both in 1991 and 1995.

While there were slight improvements in most indicators of disease severity between
1991 and 1995, these changes were not significant except in relation to the frequency
of use of p-agonist inhalers. Reductions in the proportion of people using p-agonist
inhalers between at least a few times a week and at least daily suggest improved
asthma management.

Changes in prescribing which have been made are in

accordance with the Asthma Management Plan with increased prescribing of inhaled
corticosteroids and a reduction in the reliance on regular use of p-agonist inhalers.
These changes have occurred in those people who have a moderate usage of Pagonist inhalers rather than those with a very high usage of P - a g o n i s t inhalers.

While most non-medication related management indicators improved slightly between
1991 and 1995, these changes were not significant. This is possibly due to a lack of
statistical power and/or that the emphasis of the asthma management plan and local
initiatives has been on better prescribing.

There has undoubtedly been an improvement in the prescribing of anti-asthma drugs
in the lllawarra between 1991 and 1995. Significant improvements in the regular use
of either inhaled corticosteroids or cromoglycate and a dramatic decrease in use of
theophylline indicates changes in prescribing in line with the recommendations of the
asthma management plan. The changes in preventative maintenance therapy have not
been as great as those put fon/vard in the National Asthma Campaign goals and targets
document.

The target is for 80 per cent of the adult asthmatic population to use

preventative maintenance therapy by 1996, based upon a baseline measure of 39 per
cent in 1990.^° The National Asthma Campaign survey reported 38 per cent using
inhaled corticosteroids or sodium cromoglycate in 1990. This increased to 43 per cent
by 1993.^^ The increase in the lllawarra from 44 per cent in 1991 to 55 per cent in 1995
suggests a higher baseline and a greater increase in the lllawarra, however this may
reflect the different serveillance methods used for the national and lllawarra estimates.
This increase was significant after adjusting for age, sex and potential measures of
disease severity (Adjusted OR = 0.87; 95% CI = 0.80-0.95; P = 0.0019).
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Table 1: Comparison of 'OTC group' and 'Prescription group' 1995

OTC group

Prescription

Odds ratio

n=171

group

(95% CI)

P value

n=312
age (years)*

34.0 (31)

48.5 (50)

-

0.001

sex (M)

56.6%+

42.8%+

1.74

0.004

(1.17-2.60)
asthma diagnosis

93.7%^

93.8%**

by doctor
chronic cough and

0.98

0.956

(0.39-2.49)
32.5%++

48.1%++

0.52

0.006

sputum
(0.32-0.85)
* Mean ages reported with median ages in parentheses. Difference tested using a ttest.
+ n=168
+ n=297
^n=142
**n=242

^n=120
«n=210

Table 2: Potential measures of disease severity compared between the 'OTC
group* and the 'Prescription group'

wheeze most or

OTC

Prescription

Adjusted

group

group

odds ratio

n=171

n=309

(95% CI)

49.1%*

67.0%^

0.55

every day
wheeze every day

P value

0.0052

(0.36-0.84)
20.4%*

33.0%+

0.66

0.0945

(0.40-1.07)
at least 5 attacks

39.2%

57.6%

in the last year
at least 10 attacks

0.0039

(0.35-0.80)
25.7%

42.4%

last year
hospital admission

0.54

0.51

0.0035

(0.33-0.80)
54.8%^

55.1%^

ever for asthma or

0.79

0.2746

(0.52-1.20)

wheeze
hospital admission
within the last 12
months
* n=167
+ n=303
^n=168
^ n=305

7.14%^

17.4%^

0.31
(0.16-0.62)

0.0009

Table 3: Weighted (and crude) prevalence estimates of factors related to the
management of adult asthma compared between the 'OTC group' and the
'Prescription group'

Total

OTC

Prescription

Adjusted

P

population

group

group

odds ratio

value

n=482

n=171

n=311

(95% CI)

objective airways measurement by

27.9%

25.4%

32.2%*

0.37

the doctor 'usually' or 'always'

(31.1%)

(23.4%)

(35.4%)

(0.21-0.67)

peak flow readings at home

28.1%

26.2%

27.8%^

0.67

(31.0%)

(25.7%)

(34.0%)

(0.38-1.17)

92.8%

92.8%

93.3%

0.87

(93.4%)

(91.8%)

(94.2%)

(0.37-2.01)

24.7%

20.5%

27.6%

0.48

(27.8%)

(20.5%)

(31.8%)

(0.26-0.88)

regular medical review at least

53.7%

45.3%^

60.7%^

0.50

once per year

(60.2%)

(42.2%)

(70.3%)

(0.27-0.93)

regular medical review at least

40.3%

33.6%^

47.9%^

0.32

twice per year

(48.4%)

(27.4%)

(60.3%)

(0.17-0.64)

instruction in inhaler technique

written action plan

* n=308
+ n=306
+ n=:135
^ n=239

0.0011

0.1597

0.7407

0.0184

0.0297

0.0009

Table 4: Weighted (and crude) prevalence estimates of the use medications
during the previous six months compared between the 'OTC group' and the
'Prescription group'

Total

OTC

Prescription

Adjusted

P

Population

group

group

odds ratio

value

n=483

n = 171

n = 312

(95% CI)

Regular inhaled corticosteroids or

57.7%

55.9%

59.5%

0.29

cromoglycate

(61.9%)

(50.3%)

(68.3%)

(0.16-0.51)

Regular ipratropium bromide

11.1%

5.96%

14.8%

0.27

(17.6%)

(5.26%)

(24.4%)

(0.09-0.88)

9.49%

8.12%

8.90%

0.30

(12.8%)

(7.02%)

(16.0%)

(0.11-0.79)

57.2%

57.0

58.2%

0.35

(60.0%)

(51.5%)

(64.7%)

(0.21-0.61)

15.7%

16.0

15.4%

0.85

(18.4%)

(15.8%)

(19.9%)

(0.43-1.66)

16.2%

13.6%

18.3%

0.44

(23.0%)

(11.1%)

(29.5%)

(0.20-0.94)

14.0%

11.9%

14.7%

0.43

(18.6%)

(11.1%)

(29.5%)

(0.20-0.94)

Regular theophylline

Any inhaled corticosteroids

Any sodium cromoglycate

Any ipratropium bromide

Any theophylline

0.0001

0.0289

0.0151

0.0002

0.6260

0.0480

0.0348

Table 5: Weighted (and crude) prevalence estimates of factors related to the
management of adult asthma compared between the 1991 and 1995
respondents

1991

1995

Adjusted

n=422

n=490

odds ratio

P value

(95% CI)
objective airways

24.1%

28.4%*

0.96

measurements by the doctor

(28.2%)

(31.4%)

(0.88-1.05)

19.5%^

27.0%^

0.94

(24.5%)

(31.3%)

(0.86-1.03)

89.6%^

90.9%

1.02

(91.9%)

(93.1%)

(0.88-1.18)

18.4%

24.9%

0.97

(22.8%)

(27.6%)

(0.89-1.07)

regular medical review at least

46.5%**

53.9%^+

0.92

once per year

(51.6%)

(60.2%)

(0.83-1.02)

regular medical review at least

36.2%**

39.7%++

0.94

twice per year

(43.3%)

(48.6%)

(0.84-1.04)

0.4036

'usually' or 'always'
peak flow readings at home

instruction in inhaler technique
written action plan

* n=487
+ n=421
^ n=485
^n=417
** n=314
^ n=379

0.2060
0.7658
0.5807
0.1127

0.2119

Table 6: Weighted (and crude) prevalence estimates of the use of medications
during the previous six months compared between 1991 and 1995
respondents

1991

1995

Adjusted odds

n = 421

n = 491

ratio

P value

(95% CI)
Regular inhaled corticosteroids or

43.7%

55.0%

0.87

cromoglycate

(51.1%)

(62.1%)

(0.80-0.95)

Regular ipratropium bromide

9.14%

10.7%

0.91

(14.0%)

(17.5%)

(0.81-1.03)

19.0%

9.58%

1.27

(24.2%)

(13.0%)

(1.14-1.41)

6.00%

5.81%

0.98

(8.39%)

(8.76%)

(0.86-1.13)

16.0%

15.3%

1.01

(15.2%)

(16.3%)

(0.91-1.13)

47.0%

55.4%

0.94

(54.6%)

(60.1%)

(0.86-1.02)

11.2%

13.5%

0.87

(13.5%)

(18.7%)

(0.77-0.97)

25.8%

13.5%

1.27

(32.6%)

(18.7%)

(1.15-1.40)

Regular theophylline

Regular oral corticosteroids

Regular antibiotics

Any inhaled corticosteroids

Any sodium cromoglycate

Any theophylline

0.0019

0.1542

0.0001

0.7894

0.8277

0.1392

0.0117

0.0001
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ILLAWARRA PUBLIC HEALTH UNIT
University of Woliongong

lllawarra Area Health Service

(Postal address)

18 Madeline Street
GWYNNEVILLE NSW 2500

KEIRAVILLE

TELEPHONE: ( 0 4 2 ) 2 6 4 6 7 7

PO Box 66
NSW 2500

FACSIMILE; (042) 2 6 4 9 1 7

TELL US ABOUT YOUR CHEST

You may have heard that the lllawarra Pharmacists and
the lllawarra Public Health Unit are doing a study about
asthma In the lllawarra.
As you know asthma Is an important health problem. To
give the best possible treatment we need to know more about
who's suffering from chest problems, how badly people are
suffering and what treatment people are having for their
asthma at the moment.
Therefore, we are asking for 3 minutes of your time to
complete this confidential questionnaire about your
chest. The questionnaire is on the reverse side of this sheet.
It is only a page long and for most questions only a tick is
needed. We do not need your name, only your age and sex.
It Is important that as many people as possible complete
these questionnaires. Your help wiii be most appreciated.
The pharmacist will be pleased to assist you if you have any
difficulties.
THANK YOU FOR YOUR COOPERATION.

CONFIDENTIAL

^ I

ILLAWARRA PHARMACISTS' ASSOCIATION

'wnrkinQ

fnapthpr

for

n healthier

community'"

Sex: M •
1.

F •

How often do you use this inhaler (puffer) ?,

less than

once a

(Ventolin, Respolin, Berotec, Bricanyl or Alupent)

onceAveek C]

week

1-4 times

5-10 times

a day

2.

How often do you v/heeze?

3.

Do you use a doctor's prescription to obtain your
inhaler?

4.

Age:

C)

svery day i
•

a few times
C]

a day

pervveek

limes a day

•

II

•

'x; - p i v v e g i i ®

mostly not

mostly

•

•

more than 10
C1

11

never

years

1

always

•

•

Has a doctor or other health worker ever shown you how io use your
inhaler correctly?

•

Of ; | | | | | i | | | B |

Yes

If YE5, who? (ea: codor. pnarmacisi, physio, nurse, hospfial casualiv)

5.

6.

How many attacks of asthma or wheezing have
you had in the last year?
How ouen does your doctor measure your
breathing with a peak flow meter or other device?

7.

Do you measure your own peak flow at home?

8.

Do you usually visit a doctor about your chest:

[

1 - 4

none

more than 10

5 - 10

•

^siSccasiofialiyl

never

•

•

•

/•-ahvays

;||||i|l|i| :||||||j|ij:
D

Yes

No

•

a._ When^your;chest;:ts;ii^

ittiil®:-^-

b. .Fqr:reGiiiar.r^

; :ivyics or more ^

''a::ye3r

9.

no, never

(lick one)

•

last year

Yes

1 10. Do you have a written plan of what to do when you have an attack?
11. Durina the last 6 months which of the following medications have you taken
for your chest? (For each group, you may tick none, one or two boxes.)
1
s.
b.
c.
d.
e.
f.
g.
h.

Ventolin, Respolin, Berotec, Bricanyl, Alupent
Atrovent
Intal
Becoiide, Becloforte or Aldecin
Nuelin, Theodur, Elixophyliin, Choledyl, Brondecon
Cortisone, Celestone, Prednisolone
Antihistamines eg: Avil, Polaramine, Zadine, Demazin, Teldane
Antibiotics eg; Penicillin, Abbocillin, Amoxyl, Augmentin, Doryx, Cecior,
Mysieclin, Vibramycin, Vibra-Tabis, Kelfex, Bactrim, Septrin, etc

12. How many times during the last 12 months have you visited a
pharmacy to obtain medication for your chest?

yes, in

yes, not in

Have you been admitted to hospital with asthma or wheezing?

last year

•

•

1 No

most of the
time

in bad attacks

•

a

•

b

•

b

•

c

•

c

•

d

•

d

•

e

•

e

•

f
g

•
•

f

g

•

•

h

•

h

•

•

•

O

a

1-2

-

D

3
more

••

'if:5-10

•

11 ' 25

O

than 25

D
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A3.2 1995 Pharmacy Exit Survey Questionnaire

^

University of Wollongong

ILLAWARRA"AR^

Illawarra Area Health Service

(Postal Address)
PO Box 66
KErRAVDLLE NSW 2500
FacsimOe: (042) 264917

18 Madeline Street
GWYNNEVILLE NSW 2500
Telephone: (042) 26 4677

TELL US ABOUT YOUR CHEST
You may have heard that the Illawarra Pharmacists and the
Illawarra Public Health Unit are doing a study about asthma In
the liiawarra. We conducted this study first In Aug-Sept 1991.
This present study Is Intended to be a repeat of that study to
see If asthma managment has Improved.
As you know asthma Is an Important health problem. To give
the best possible treatment we need to know more .about who's
suffering from chest problemsiliow bldly people are suffering and
what treatment people are having for their asthma at the moment.
Therefore^ we are asking forjs minutes of your time to
complete this confidential questionnaire about your chest. The
questionnaire is on the reverse side of this sheet. It is only a page
Jong and for most questions only a tick is needed. We do not need,
"your namei^^^only your age and sex. You are under no obligation to
cqmplete the questionnaire though we would appreciate you doing
;:S0.

it is Important that as many people as possible complete these
questionnaires. Your help wiil be most appreciated.
The
/pharmacist will be pleased to assist you if you have any difficulties.
;:lf you have any;enquiries regarding the conduct of the research
please contact ^the Secretary of the University of Wollongong
{-iuman ResearC: Ethics Committee on (042) 213 457.

I understand the data collected will be used for a repeal study Into asthma
mnagniM
and I consent for the data to be used In UiBwanner.

If you wish to take part in this research please sign below::

"working together for a healthier

community

PHARMACY EXIT SURVEY

1. How often do you use an inhaler
Berotec, Bricanyl, Alupent,Asmol.Serevent
1—

2. How often do you wheeze?

less than
onceAveek •
1-4 times a
day
•

( p u f f e r ) ? V e n t o i i n . Respoiin.
only

r^::-;

'•

i 3. Do you use a doctor's prescription .to obtain this
' inhaler
J .

every day

never

SEX: M •

•

•

most days

•

mostly not

•

F•

Age:

once a week

•

_years

5-10 times
a day

•

a few times
per week
more than 10
times a day

about once a
week

•

less than once a
week
•

mostly

•

aKvays

•

•

No
•

Yes

^ 4. Has your doctor or other health worker ever shown you how to use your
i
inhaler correctly?

•

If YES who ? (e.a. doctor, pharmacist, physio, nurse, hospital casualty):
none
•

1-4
•

5-10
• •

never
•

occasionally
•

usually
•

5. How many attacks of asthma or wheezing have
you had in the last year?
6. How often does your doctor measure your
breathing with a peak flow meter or other
device?
7 Do you measure your own peak flow meter at home?

more than 10
•

always
•

Yes

•

No

•

Yes
Yes
Once a year

•
•
•

No
•
No
•
Twice or more a
year
•

yes, not in last
year
•

yes, in last y e a r D

8. Do you usually visit a doctor about your chest:
a. When your chest is causing problems ?
b. For regular review, even if your chest is not causing problems ?
If Yes to b, - how often ?

9. Have you been admitted to hospital with asthma or
wheezina? (tick one)

Less than
once a yearO

no, never

•

Yes

10.DO you have a written plan of what to do when you have an attack?

•

No

in bad attacks

most of the
time

H.Dijnna the last 6 months which of the following medications have you
taken? (tick one or more)

•

a. Ventolin, Respoiin, Berotec, Bricanyl, Alupent,Asmol.Serevent

12.H0W many times during the last 12 months have you visited
a pharmacy to obtain medication for your chest?
13.During the last 12 months how many times have you been
to a community pharmacy to have a prescription filled for
a n y o f t h e f o l l o w i n g : v e n t o l m , Respoiin, Berotec, Bricanyl,
Alupent,Asmol,Serevent?

g

•
•
•
•
•
•

•

a
b
c
d
e
f
g

•
•
•
•
•
•
•

h

•

h

•

a
b
c
d
e
f

b. Atrovent, Tilade, Fiixotide
c. Intal
d. Becotide, Becloforte, Aldecin or Pulmicort
e. Nuelin, Theodur, Elixophyllin, Choledyl or Brondecon
f. Cortisone, Celestone or Prednisolone
q. Antihistamines e.g.iAvil, Polaramine, Zadine, Demazin,TeIdane
. ,
h Antibiotics e.g.: Penicillin, Abbociilin, Amoxyl, Augmentin, Doryx, Ceclor, Mys.eclm,
Vibramydn,Vibra-Tabs, Keflex, Bactrim, Septrin, Rulide, Erythromycin etc.

none

•

1-2

•

3-4

•

5-10

•

11-25

•

more than 25

•

none

•

1-2

•

3-4

•

5-10

•

11-25

•

more than 25

•

APPENDIX 4 : Results of reanalysis of 1991 Pharmacy Exit Survey
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group'
Table A4.5: Weighted (and crude) prevalence estimates of the use medications
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Table A4.6: Weighted (and crude) prevalence estimates of use of medications at any
time during the previous six months compared between the 'OTC group' and the
'Prescription group'

Table A4.1: Comparison of questionnaire respondents and non-respondents

Respondents

Nonrespondents

Odds Ratio
(95% CI)

P value

age (years)*

42.2 (40)
n = 429

38.2 (32)
n = 107

-

0.036

sex(M)

53.3%
n = 422

54.1%
n = 98

0.97
(0.61-1.54)

0.891

asthma
diagnosis by
doctor

95.4%
n = 324

87.2%
n = 94

3.01
(1.27-7.14)

0.005

chronic cough
and sputum

46.2%
n = 238

44.7%
n = 74

1.26
(0.72-2.22)

0.391

obtained
42.6%
64.6%
0.41
0.00013
medication
n = 312
n = 99
(0.25-0.67)
'over-thecounter'
* Mean ages reported with median ages in parentheses. Difference tested using a ttest.

Table A4.2: Comparison of 'OTC group' and 'Prescription group'

OTC group

Prescription
group

Odds ratio
(95% CI)

P value

age (years)*

35.1 (32)
n = 164

46.6 (47)
n = 259

_

0.001

sex (M)

62.2%
n = 164

48.8%
n = 252

1.73
(1.13-2.63)

0.007

asthma diagnosis
by doctor

94.4%
n = 126

95.9%
n = 194

0.73
(0.23-2.31)

0.554

chronic cough and 31.9%
54.5%
0.39
0.001
sputum
n = 145
n = 91
(0.22-0.70)
* Mean ages reported with median ages in parentheses. Difference tested using a ttest.

Table A4.3: Potential measures of disease severity compared between the 'OTC
group' and the 'Prescription group'

OTC
group

Prescription
group

Crude
odds ratio
(95% CI)

Adjusted
odds ratio
(95% CI)

P
value

wheeze at least
once per week

76.3%
n = 156

79.7%
n = 246

0.82
(0.49-1.37)

0.83
(0.39-1.04)

0.4628

wheeze most or
every day

57.1%
n = 156

67.5%
n = 246

0.64
(0.41-0.99)

0.75
(0.48-1.16)

0.1984

wheeze every day

21.8%
n = 156

34.2%
n = 246

0.54
(0.33-0.87)

0.64
(0.50-1.38)

0.0700

at least 5 attacks
in the last year

52.8%
n = 163

54.7%
n = 256

0.93
(0.61-1.40)

1.01
(0.66-1.53)

0.9662

at least 10 attacks
last year

35.6%
n = 163

42.2%
n = 256

0.76
(0.49-1.16)

0.85
(0.55-1.31)

0.4548

hospital admission
ever for asthma or
wheeze

43.2%
n = 162

55.0%
n = 258

0.62
(0.41-0.94)

0.64
(0.42-0.97)

0.0370

hospital admission
within the last 12
months

7.41%
n = 162

19.4%
n = 258

0.33
(0.16-0.67)

0.37
(0.18-0.73)

0.0046

use of betaagonist puffer at
least daily

68.8%
n = 160

79.3%
n = 256

0.57
(0.36-0.92)

0.77
(0.48-1.24)

0.2903

use of betaagonist puffer at
least 5 times daily

10.6%
n = 162

18.4%
n = 258

0.53
(0.28-0.99)

0.71
(0.37-1.34)

0.2916

more than 25
visits to pharmacy
for medication

9.94%
n = 161

25.8%
n = 256

0.32
(0.17-0.59)

0.43
(0.23-0.79)

0.0070

Table A4.4: Weighted (and crude) prevalence estimates of factors related to the
management of adult asthma compared between the 'OTC group' and the
'Prescription group'

Total
population

OTC
group

Prescription
group

Crude
odds ratio
(95% CI)

Adjusted
odds ratio
(95% CI)

P
value

objective airways
measurement by the
doctor 'usually' or
'always'

24.1%
(28.4%)

14.7%
(16.6%)
n = 163

31.2%
(35.9%)
n = 256

0.35
(0.210.59)

0.44
(0.240.83)

0.0107

peak flow readings
at home

19.5%
(24.4%)

16.6%
(19.1%)
n = 162

22.6%
(27.7%)
n = 256

0.62
(0.371.02)

0.59
(0.321.09)

0.0942

instruction in inhaler
technique

89.6%
(91.9%)

90.9%
(90.2%)
n = 163

88.6%
(93.0%)
n = 256

0.69
(0.331.48)

1.28
(0.513.23)

0.6008

written action plan

18.4%
(23.0%)

14.9%
(17.1%)
n = 158

21.2%
(26.6%)
n = 256

0.57
(0.340.96)

0.65
(0.351.22)

0.1805

regular medical
review at least once
per year

46.5%
(51.6%)

26.5%
(28.6%)
n = 119

58.5%
(66.0%)
n = 191

0.21
(0.120.35)

0.31
(0.170.59)

0.0003

regular medical
review at least twice
per year

36.2%
(43.6%)

19.6%
(21.9%)
n = 119

45.0%
(57.1%)
n = 191

0.21
(0.120.36)

0.35
(0.180.67)

0.0017

Table A4.5: Weighted (and crude) prevalence estimates of the use medications
regularly during the previous six months compared between the 'OTC group' and
the 'Prescription group'

Total
population
n = 423

OTC
group
n = 164

Prescription
group
n = 259

Crude
odds
ratio

Adjusted
odds
ratio
(95% CI)

P
value

inhaled
corticosteroids
or
cromoglycate

43.7%
(51.5%)

35.3%
(38.4%)

49.0%
(59.9%)

0.42
(0.270.64)

0.54
(0.310.92)

0.0240

inhaled
corticosteroids

39.3%
(46.8%)

32.0%
(34.2%)

44.7%
(54.8%)

0.43
(0.280.65)

0.49
(0.280.83)

0.0087

cromoglycate

9.12%
(10.4%)

10.8%
(10.4%)

8.08%
(10.4%)

0.99
(0.501.97)

2.44
(0.956.27)

0.0642

ipratropium

9.14
(14.2%)

2.50%
(3.66%)

12.7%
(20.9%)

0.14
(0.050.36)

0.29
(0.100.83)

0.0216

theophylline

19.0
(24.6%)

14.7%
(14.0%)

23.3%
(31.3%)

0.36
(0.210.62)

0.59
(0.301.16)

0.1271

oral
corticosteroids

6.00
(8.51%)

1.74%
(2.44%)

8.87%
(12.4%)

0.18
(0.050.54)

0.19
(0.050.70)

0.0124

antibiotics

16.0
(15.4%)

10.1%
(9.76%)

19.8%
(18.9%)

0.46
(0.240.88)

0.48
(0.221.06)

0.0686

Table A4.6: Weighted (and crude) prevalence estimates of use of medications at
any time during the previous six months compared between the 'OTC group' and
the 'Prescription group'
Total
population
n = 428

OTC
group
n = 164

Prescription
group
n = 259

Crude
odds
ratio
(95% CI)

Adjusted
odds
ratio
(95% CI)

P
value

inhaled
corticosteroids

47.0%
(55.1%)

40.0%
(43.3%)

53.0%
(62.6%)

0.46
(0.300.69)

0.50
(0.300.86)

0.0122

cromoglycate

11.2%
(13.5%)

12.8%
(13.4%)

10.3%
(13.5%)

0.99
(0.541.82)

1.85
(0.834.12)

0.1346

ipratropium

13.9%
(20.6%)

8.07%
(9.76%)

17.0%
(27.4%)

0.29
(0.150.53)

0.34
(0.160.74)

0.0063

theophylline

25.8%
(33.1%)

22.0%
(24.4%)

29.2%
(27.4%)

0.51
(0.320.81)

0.73
(0.411.30)

0.2896

oral
corticosteroids

15.4%
(21.8%)

11.1%
(14.0%)

19.0%
(26.6%)

0.45
(0.260.78)

0.66
(0.331.31)

0.2332

antihistamines

12.9%
(13.7%)

14.8%
(14.6%)

12.1%
(13.1%)

1.13
(0.622.06)

0.90
(0.441.83)

0.7683

antibiotics

35.0%
(31.9%)

27.7%
(27.4%)

40.0%
(42.9%)

0.50
(0.320.79)

0.48
(0.280.83)

0.0090

APPENDiX jS; Tables of weighted and crude prevalence estimates of management
factors and use of medication. Weighting factors are based upon self reported
frequency of pharmacy visits to obtain anti-asthma medication.
Contents:
Table A5.1: Weighted (and crude) prevalence estimates of factors related to the
management of adult asthma compared between the 'OTC group' and the 'Prescription
group'
Table A5.2: Weighted (and crude) prevalence estimates of the use medications
regularly during the previous six months compared between the 'OTC group' and the
'Prescription group'
Table A5.3: Weighted (and crude) prevalence estimates of use of medications at any
time during the previous six months compared between the 'OTC group' and the
'Prescription group'

Table A5.1: Weighted (and crude) prevalence estimates of factors related to the
management of adult asthma compared between the 'OTC group' and the
'Prescription group'

Total
population

objective airways
measurement by the
doctor 'usually' or

28.4%
(31.1%)

'always'
peak flow readings
at home

instruction in inhaler
technique

written action plan

regular medical
review at least once
per year
regular medical
review at least twice
per year

OTC
group

Prescription
group

Crude

Adjusted

odds ratio

odds ratio

(95% CI)

(95% CI)
0.37
(0.21-

21.3%
(23.4%)

32.5%
(35.4%)

n = 171

n = 308

0.56
(0.360.87)

P value

0.0011

0.67)

-

27.0%
(31.0%)

21.7%
(25.7%)
n = 171

29.8%
(34.0%)
n = 306

0.69
(0.451.08)

0.67

90.9%
(93.4%)

89.6%

92.0%
(94.2%)

0.69
(0.32-

0.87
(0.37-

n = 311

1.51)

2.01)

(91.8%)
n = 171

0.1597

(0.381.17)
0.7407

24.9%
(27.8%)

18.9%
(20.5%)
n = 171

28.7%

0.55
(0.350.88)

0.48
(0.260.88)

0.0184

(31.8%)
n = 311

53.9%
(60.2%)

43.2%
(42.2%)

60.7%

0.31

0.0297

(70.3%)
n = 239

(0.190.49)

0.50
(0.270.93)

48.4%

0.25
(0.150.40)

0.32
(0.170.64)

0.0009

(60.3%)
n = 239

n = 135
39.7%
(48.4%)

25.2%
(27.4%)
n = 135

Table A5.2: Weighted (and crude) prevalence estimates of the use medications
regularly during the previous six months compared between the 'OTC group' and
the 'Prescription group'

Total
population
n = 483

OTC
group
n = 171

Prescription
group
n = 312

Crude
odds
ratio

Adjusted
odds
ratio
(95% CI)

P
value

inhaled
corticosteroids
or
cromoglycate

55.0
(61.9%)

43.4%
(50.3%)

61.6%
(68.3%)

0.47
(0.310.70)

0.29
(0.160.51)

0.0001

inhaled
corticosteroids

48.8%
(54.2%)

37.9%
(44.4%)

53.9%
(59.6%)

0.54
(0.370.80)

0.35
(0.200.60)

0.0001

cromoglycate

13.4%
(16.4%)

10.8%
(11.7%)

14.6%
(18.9%)

0.57
(0.321.01)

0.67
(0.321.37)

0.2679

ipratropium

10.7%
(17.6%)

4.40%
(5.26%)

14.5%
(24.4%)

0.17
(0.080.37)

0.27
(0.090.88)

0.0289

theophylline

9.58%
(12.8%)

5.07%
(7.02%)

11.7%
(16.0%)

0.40
(0.190.79)

0.30
(0.110.79)

0.0151

oral
corticosteroids

5.81%
(8.70%)

5.30%
(5.85%)

6.20%
(10.3%)

0.54
(0.241.19)

1.45
(0.504.21)

0.4974

antibiotics

15.3%
(15.9%)

9.73%
(11.1%)

18.2%
(18.6%)

0.55
(0.240.88)

0.83
(0.411.70)

0.6118

Table A5.3: Weighted (and crude) prevalence estimates of use of medications at
any time during the previous six months compared between the 'OTC group' and
the 'Prescription group'
Total
population
n = 477

OTC
group
n = 171

Prescription
group
n = 306

Crude
odds
ratio
(95% CI)

Adjusted
odds
ratio
(95% CI)

P
value

inhaled
corticosteroids

55.4%
(60.0%)

47.0
(51.5%)

60.1%
(64.7%)

0.58
(0.390.86)

0.35
(0.210.61)

0.0002

cromoglycate

15.7%
(18.4%)

12.8%
(15.8%)

15.7%
(19.9%)

0.76
(0.451.28)

0.85
(0.431.66)

0.6260

ipratropium

15.5%
(23.0%)

10.4%
(11.1%)

18.4%
(29.5%)

0.30
(0.170.53)

0.44
(0.200.94)

0.0480

theophylline

13.5%
(18.6%)

7.79%
(11.1%)

16.6%
(29.5%)

0.42
(0.240.75)

0.43
(0.200.94)

0.0348

oral
corticosteroids

18.4%
(24.2%)

16.8%
(19.9%)

19.3%
(26.6%)

0.68
(0.421.10)

1.00
(0.521.94)

0.9916

antihistamines

15.3%
(16.8%)

16.1%
(18.7%)

15.4%
(15.7%)

1.24
(0.732.07)

2.76
(1.385.52)

0.0042

antibiotics

35.1%
(38.9%)

31.2%
(32.8%)

37.2%
(42.3%)

0.66
(0.441.00)

1.12
(0.661.88)

0.6791

APPENDIX 6.- Comparison of 1991 and 1995 factors related to management with
frequency of p-agonist use removed from the logistic regression model.

Contents:
Table A6.1: Weighted (and crude) prevalence estimates of factors related to the
management of adult asthma compared between the 1991 and 1995 respondents

Table A6.1: Weighted (and crude) prevalence estimates of factors related to the
management of adult asthma compared between the 1991 and 1995 respondents

1991

1995

Crude
odds ratio
(95% CI)

Adjusted
odds ratio
(95% CI)

P
value

objective airways
measurements by the
doctor 'usually' or
'always'

24.1%
(28.2%)
n = 422

28.4%
(31.4%)
n = 487

0.86
(0.64-1.15)

0.96
(0.88-1.05)

0.4036

peak flow readings at
home

19.5%
(24.5%)
n = 421

27.0%
(31.3%)
n = 485

0.71
(0.52-0.96)

0.94
(0.85-1.03)

0.2060

instruction in inhaler
technique

89.6%
(91.9%)
n = 421

90.9%
(93.1%)
n = 490

0.85
(0.50-1.43)

1.03
(0.89-1.19)

0.7658

written action plan

18.4%
(22.8%)
n = 417

24.9%
(27.6%)
n = 490

0.78
(0.57-1.06)

0.97
(0.89-1.07)

0.5807

regular medical review
at least once per year

46.5%
(51.6%)
n = 314

53.9%
(60.2%)
n = 379

0.71
(0.52-0.97)

0.93
(0.84-1.03)

0.1127

regular medical review
at least twice per year

36.2%
(43.3%)
n = 314

39.7%
(48.6%)
n = 379

0.81
(0.59-1.11)

0.93
(0.84-1.03)

0.2119
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